Method and system for automated neurocognitive training to extend remission of refractory psychiatric disorders
By combining automated neurocognitive training within a critical time period after ketamine administration, using conditioned action sequences and stimulation to perform Pavlov conditioning, the problem of short-term effects of fast-acting pharmacological preparations and unreliable effects of automated neurocognitive training was solved. , achieving rapid and lasting relief of depression.
Patent Information
- Application Number
- CN202380029057.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-03
- Filing Date
- 2023-03-02
- Publication Date
- 2024-11-08
AI Technical Summary
In the treatment of depression, although fast-acting pharmacological preparations such as ketamine show rapid relief effects, the effects are short-term and reusable safety and feasibility problems, and the clinical effect of automated neurocognitive training is unreliable, making it difficult to achieve rapid , lasting relief.
Combining fast-acting antidepressants with automated neurocognitive training, Pavlov conditioning is promoted by conducting multiple automated neurocognitive training sessions within a critical time period after drug administration, using conditioned action sequences and stimulation pairs to promote positive effects. Implicit self-representation and self-worth enhance patients' participation in cognitive training.
Achieve rapid relief effects that appear within 1 day and last for at least 3 months within 30 days. A brief course of treatment, fully automated, portable and not resource-intensive, suitable for a variety of environments, especially in patients with refractory depression. Effective.
Smart Images

Figure CN118922127A_ABST
Abstract
Description
[0001] Cross-references to related patent applications
[0002] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 316,098, filed on March 3, 2022, entitled “METHODS AND SYSTEMS FOR AUTOMATEDNEUROCOGNITIVE TRAINING TO EXTEND RELIEF OF TREATMENT-RESISTANT MENTALDISORDERS,” the disclosure of which is expressly incorporated herein by reference in its entirety.
[0003] Statement Regarding Federally Funded Research
[0004] This invention was made with support from the National Institutes of Health under Grant Nos. MH113857 and MH124983. The Government has certain rights in this invention. Background Art
[0005] Depression is a leading cause of disability worldwide, with a public burden of disease reaching staggering proportions. Although effective treatments have been available for decades, remission rates are low, relapse rates are high, and the prevalence of the disorder remains remarkably consistent, with only 12.7% of patients receiving minimal treatment. Suicide is the most tragic outcome of depression, claiming 1 million lives worldwide each year. Despite focused research and clinical efforts to address this tragic need, suicide rates in the United States have continued to rise in recent years. 80% of those who die by suicide had been seen in a health care setting in the year prior to death, suggesting that the system as a whole is missing a critical opportunity to reach these patients and implement effective suicide prevention strategies. New innovative treatments that are accessible, portable, and easily disseminated are urgently needed to address these public health crises.
[0006] The development of interventions for depression has increasingly sought to leverage technology to increase patient access, reduce costs, and minimize adverse outcomes through the use of automated computer-based processes / software. Over the past decade, there has been growing interest in automated “cognitive training” (CT) treatments designed to directly modulate affective processing patterns to reduce symptoms; however, despite showing promise, clinical effects have been unreliable, particularly in patients with acute depression, and relief has typically taken weeks to provide. Meanwhile, rapidly acting pharmacological agents, such as ketamine at subanesthetic doses, have offered promise for breakthroughs in the management of depression, but this promise has yet to be realized. Studies have shown response rates of 55%–80% in patients with depression as early as 2 hours after ketamine administration, even in patients resistant to conventional treatment, suggesting that ketamine has the potential to provide immediate relief for many patients. However, the effects of a single infusion dissipate almost as quickly (3–7 days), posing a significant challenge to clinical translation given concerns about the safety and feasibility of repeated ketamine administration. Furthermore, the majority of patients with depression express a preference for treatments that involve a behavioral / learning component (e.g., up to 91% of those enrolled in drug trials). The practical challenges of maintaining medication regimens over time further demonstrate that multiple approaches are needed to achieve rapid, durable remission. Summary of the invention
[0007] In some embodiments, the technology described herein relates to a method for treating a patient suffering from a psychiatric disorder, comprising: administering to the patient a drug having an antidepressant effect; and administering to the patient a neurocognitive training protocol during a critical time period after the administration of the drug. The step of administering the neurocognitive training protocol to the patient comprises delivering to the patient a plurality of automated neurocognitive training sessions using a computing device, wherein during the delivery of each automated neurocognitive training session, a plurality of conditioning sequences are presented to the patient, each respective conditioning sequence comprising a respective non-self-relevant stimulus and a respective self-relevant stimulus.
[0008] In some embodiments, a first automated neurocognitive training session and a second automated neurocognitive training session are delivered to the patient on a first day, and a third automated neurocognitive training session and a fourth automated neurocognitive training session are delivered to the patient on a second day. Optionally, the time period between the delivery of the first and second automated neurocognitive training sessions to the patient is about 20 minutes or longer. Optionally, the time period between the delivery of the third and fourth automated neurocognitive training sessions to the patient is about 20 minutes or longer.
[0009] In some embodiments, each automated neurocognitive training session has a duration of between about 15 minutes and about 20 minutes.
[0010] In some embodiments, the plurality of automated neurocognitive training sessions is between about 2 sessions to about 14 sessions. Optionally, the plurality of automated neurocognitive training sessions is about 8 sessions.
[0011] In some embodiments, each respective conditioning sequence further comprises a task that is presented to the patient subsequent to or in conjunction with presentation of a respective non-self-relevant and self-relevant stimulus pair.
[0012] In some embodiments, the respective non-self-relevant stimulus and / or the respective self-relevant stimulus used in the respective conditioning sequence is an auditory stimulus. In some embodiments, the respective non-self-relevant stimulus and / or the respective self-relevant stimulus used in the respective conditioning sequence is a visual stimulus.
[0013] In some embodiments, the respective self-related stimulus for the respective conditioning sequence comprises a sound, image, or word associated with the patient. Optionally, the respective non-self-related stimulus for the respective conditioning sequence comprises a sound, image, or word associated with positive meanings. Optionally, the respective non-self-related stimulus for the respective conditioning sequence comprises a sound, image, or word associated with life-affirming meanings.
[0014] In some embodiments, the respective non-self-relevant stimuli and the respective self-relevant stimuli for the respective conditioning sequences are included in an nxm matrix comprising a plurality of visual stimuli. Optionally, the step of administering the neurocognitive training protocol to the patient further comprises receiving from the patient a selection of matching the respective non-self-relevant stimuli with the respective self-relevant stimuli for the respective conditioning sequences.
[0015] In some embodiments, one or more of the plurality of conditioning sequences comprises subthreshold presentation of a non-self-relevant stimulus or a self-relevant stimulus. In some embodiments, one or more of the plurality of conditioning sequences comprises suprathreshold presentation of a non-self-relevant stimulus or a self-relevant stimulus.
[0016] In some embodiments, the computing device includes a processor and a memory operably connected to the processor, the memory having computer executable instructions stored thereon. Optionally, the memory has computer executable instructions stored thereon, which, when executed by the processor, cause the processor to generate each respective conditional action sequence.
[0017] In some embodiments, the computing device also includes a display device operably connected to the processor, and wherein the memory has computer executable instructions stored thereon that, when executed by the processor, cause the processor to: generate graphical data for each respective conditional action sequence; and cause the graphical data to be displayed on the display device.
[0018] In some embodiments, the critical time period is the time period during which the drug rapidly proliferates synaptic contacts in the patient's brain. In some embodiments, the critical time period is between about 2 hours to about 14 days after administration of the drug. In some embodiments, the critical time period is between about 1 day to about 5 days after administration of the drug.
[0019] In some embodiments, the drug is a fast-acting antidepressant. In some embodiments, the fast-acting antidepressant is ketamine. In some embodiments, the drug is brexanolone, zuranolone, rapastinel, scopolamine, or a hallucinogen.
[0020] In some embodiments, the psychiatric disorder is depression. In some embodiments, the psychiatric disorder is suicidal behavior.
[0021] In some embodiments, the technology described herein relates to a computer-implemented method for administering a neurocognitive training protocol to a patient with a psychiatric disorder who has received a medication having an antidepressant effect, and administering the neurocognitive training protocol during a critical time period after the medication is administered to the patient. The computer-implemented method includes delivering a plurality of automated neurocognitive training sessions to the patient, wherein during the delivery of each automated neurocognitive training session, a plurality of conditioning sequences are presented to the patient, each respective conditioning sequence comprising a respective non-self-relevant stimulus and a respective self-relevant stimulus.
[0022] In some embodiments, a first automated neurocognitive training session and a second automated neurocognitive training session are delivered to the patient on a first day, and a third automated neurocognitive training session and a fourth automated neurocognitive training session are delivered to the patient on a second day. Optionally, the time period between the delivery of the first and second automated neurocognitive training sessions to the patient is about 20 minutes or longer. Optionally, the time period between the delivery of the third and fourth automated neurocognitive training sessions to the patient is about 20 minutes or longer.
[0023] In some embodiments, each automated neurocognitive training session has a duration of between about 15 minutes and about 20 minutes.
[0024] In some embodiments, the plurality of automated neurocognitive training sessions is between about 2 sessions to about 14 sessions. Optionally, the plurality of automated neurocognitive training sessions is about 8 sessions.
[0025] In some embodiments, each respective conditioning sequence further comprises a task that is presented to the patient subsequent to or in conjunction with presentation of a respective non-self-relevant and self-relevant stimulus pair.
[0026] In some embodiments, the respective non-self-relevant stimulus and / or the respective self-relevant stimulus used in the respective conditioning sequence is an auditory stimulus. In some embodiments, the respective non-self-relevant stimulus and / or the respective self-relevant stimulus used in the respective conditioning sequence is a visual stimulus.
[0027] In some embodiments, the respective self-related stimulus for the respective conditioning sequence comprises a sound, image, or word associated with the patient. Optionally, the respective non-self-related stimulus for the respective conditioning sequence comprises a sound, image, or word associated with positive meanings. Optionally, the respective non-self-related stimulus for the respective conditioning sequence comprises a sound, image, or word associated with life-affirming meanings.
[0028] In some embodiments, the respective non-self-relevant stimuli and the respective self-relevant stimuli for the respective conditioning sequence are included in an nxm matrix including the plurality of visual stimuli. Optionally, the computer-implemented method further comprises receiving from the patient a selection matching the respective non-self-relevant stimuli with the respective self-relevant stimuli for the respective conditioning sequence.
[0029] In some embodiments, one or more of the plurality of conditioning sequences comprises subthreshold presentation of a non-self-relevant stimulus or a self-relevant stimulus. In some embodiments, one or more of the plurality of conditioning sequences comprises suprathreshold presentation of a non-self-relevant stimulus or a self-relevant stimulus.
[0030] In some embodiments, the computer-implemented method further comprises generating each respective conditioning sequence.
[0031] In some embodiments, the computer-implemented method further comprises: generating graphical data for each respective conditioning sequence; and causing the graphical data to be displayed on a display device.
[0032] In some embodiments, the critical time period is the time period during which the drug rapidly proliferates synaptic contacts in the patient's brain. In some embodiments, the critical time period is between about 2 hours to about 14 days after administration of the drug. In some embodiments, the critical time period is between about 1 day to about 5 days after administration of the drug.
[0033] In some embodiments, the technology described herein relates to a system for administering a neurocognitive training protocol to a patient with a psychiatric disorder who has received a medication having an antidepressant effect, and administering the neurocognitive training protocol during a critical time period after the medication is administered to the patient. The system includes: a processor and a memory operably connected to the processor, the memory having computer executable instructions stored thereon, the computer executable instructions, when executed by the processor, causing the processor to: deliver a plurality of automated neurocognitive training sessions to the patient, wherein during the delivery of each automated neurocognitive training session, a plurality of conditioning sequences are presented to the patient, each respective conditioning sequence comprising a respective non-self-relevant stimulus and a respective self-relevant stimulus.
[0034] In some embodiments, a first automated neurocognitive training session and a second automated neurocognitive training session are delivered to the patient on a first day, and a third automated neurocognitive training session and a fourth automated neurocognitive training session are delivered to the patient on a second day. Optionally, the time period between the delivery of the first and second automated neurocognitive training sessions to the patient is about 20 minutes or longer. Optionally, the time period between the delivery of the third and fourth automated neurocognitive training sessions to the patient is about 20 minutes or longer.
[0035] In some embodiments, each automated neurocognitive training session has a duration of between about 15 minutes and about 20 minutes.
[0036] In some embodiments, the plurality of automated neurocognitive training sessions is between about 2 sessions to about 14 sessions. Optionally, the plurality of automated neurocognitive training sessions is about 8 sessions.
[0037] In some embodiments, each respective conditioning sequence further comprises a task that is presented to the patient subsequent to or in conjunction with presentation of a respective non-self-relevant and self-relevant stimulus pair.
[0038] In some embodiments, the respective non-self-relevant stimulus and / or the respective self-relevant stimulus used in the respective conditioning sequence is an auditory stimulus. In some embodiments, the respective non-self-relevant stimulus and / or the respective self-relevant stimulus used in the respective conditioning sequence is a visual stimulus.
[0039] In some embodiments, the respective self-related stimulus for the respective conditioning sequence comprises a sound, image, or word associated with the patient. Optionally, the respective non-self-related stimulus for the respective conditioning sequence comprises a sound, image, or word associated with positive meanings. Optionally, the respective non-self-related stimulus for the respective conditioning sequence comprises a sound, image, or word associated with life-affirming meanings.
[0040] In some embodiments, the respective non-self-relevant stimuli and the respective self-relevant stimuli for the respective conditioning sequences are included in an nxm matrix including a plurality of visual stimuli.
[0041] In some embodiments, one or more of the plurality of conditioning sequences comprises subthreshold presentation of a non-self-relevant stimulus or a self-relevant stimulus. In some embodiments, one or more of the plurality of conditioning sequences comprises suprathreshold presentation of a non-self-relevant stimulus or a self-relevant stimulus.
[0042] In some embodiments, the memory has additional computer executable instructions stored thereon that, when executed by the processor, cause the processor to generate each respective conditional action sequence.
[0043] In some embodiments, the memory has stored thereon additional computer executable instructions that, when executed by the processor, cause the processor to generate graphical data for each respective conditioning sequence; and cause the graphical data to be displayed on a display device.
[0044] In some embodiments, the technology described herein relates to a method for treating a patient suffering from a psychotic disorder, comprising: administering to the patient a drug having an antidepressant effect; and administering to the patient a neurocognitive training protocol during a critical time period after the administration of the drug. The step of administering the neurocognitive training protocol to the patient comprises delivering to the patient a plurality of automated neurocognitive training sessions using a computing device. In addition, each respective automated neurocognitive training session comprises: presenting to the patient, using the computing device, an nxm matrix comprising a plurality of visual stimuli, the plurality of visual stimuli comprising a first matching pair of non-self-related and self-related visual stimuli; and receiving, using the computing device, a selection by the patient of the first matching pair of non-self-related and self-related visual stimuli.
[0045] In some embodiments, each respective automated neurocognitive training session further comprises: presenting to the patient a second matched pair of non-self-relevant and self-relevant visual stimuli using a computing device; and presenting to the patient a task using the computing device after or in connection with presentation of the second matched pair of non-self-relevant and self-relevant visual stimuli.
[0046] In some embodiments, each respective automated neurocognitive training session further comprises: presenting a self-relevant visual stimulus to the patient using a computing device; presenting a task to the patient using the computing device after or in connection with the presentation of the self-relevant stimulus; and presenting a positive non-self-relevant visual stimulus using the computing device after the patient successfully completes the task.
[0047] In some embodiments, each automated neurocognitive training session has a duration of between about 15 minutes and about 20 minutes.
[0048] In some embodiments, the critical time period is the time period during which the drug rapidly proliferates synaptic contacts in the patient's brain. In some embodiments, the critical time period is between about 2 hours to about 14 days after administration of the drug. In some embodiments, the critical time period is between about 1 day to about 5 days after administration of the drug.
[0049] In some embodiments, the technology described herein relates to a computer-implemented method for administering a neurocognitive training protocol to a patient with a psychiatric disorder who has received a medication having an antidepressant effect, and administering the neurocognitive training protocol during a critical time period after the medication is administered to the patient. The computer-implemented method includes: presenting to the patient an nxm matrix comprising a plurality of visual stimuli, the plurality of visual stimuli comprising a first matching pair of non-self-related and self-related visual stimuli; and receiving a patient's selection of the first matching pair of non-self-related and self-related visual stimuli.
[0050] In some embodiments, the technology described herein relates to a system for administering a neurocognitive training protocol to a patient with a psychiatric disorder who has received a medication having an antidepressant effect, and administering the neurocognitive training protocol during a critical time period after the medication is administered to the patient. The system includes: a processor and a memory operably connected to the processor, the memory having computer executable instructions stored thereon, the computer executable instructions, when executed by the processor, causing the processor to: present to the patient an nxm matrix comprising a plurality of visual stimuli, the plurality of visual stimuli comprising a first matching pair of non-self-related and self-related visual stimuli; and receiving a selection by the patient of the first matching pair of non-self-related and self-related visual stimuli.
[0051] In some embodiments, the technology described herein relates to a method for treating a patient suffering from a psychiatric disorder, comprising: administering to the patient a drug having an antidepressant effect; and administering to the patient a neurocognitive training protocol during a critical time period after the administration of the drug. The step of administering the neurocognitive training protocol to the patient comprises delivering to the patient a plurality of automated neurocognitive training sessions using a computing device, wherein during the delivery of each automated neurocognitive training session, a plurality of conditioning sequences are presented to the patient.
[0052] In some embodiments, the technology described herein relates to a method for conditioning a therapeutic association in a patient, comprising: administering a neuroplasticity enhancement therapy to the patient; and administering a neurocognitive training protocol to the patient during a critical time period after the administration of the neuroplasticity enhancement therapy. The step of administering the neurocognitive training protocol to the patient comprises delivering one or more conditioning sequences configured for conditioning the therapeutic association to the patient using a computing device. In some embodiments, the neuroplasticity enhancement therapy is a drug. In other embodiments, the neuroplasticity enhancement therapy is a neuromodulatory intervention.
[0053] It should be appreciated that the above-described subject matter may also be implemented as a computer-controlled apparatus, a computer process, a computing system, or as an article of manufacture such as a computer-readable storage medium.
[0054] Other systems, methods, features and / or advantages will or may become apparent to one skilled in the art upon review of the following drawings and detailed description. It is intended that all such additional systems, methods, features and / or advantages be included within this description and be protected by the accompanying claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0055] The components in the drawings are not necessarily drawn to scale relative to each other. Like reference numerals indicate corresponding parts throughout the several views.
[0056] Figure 1 is a flow chart illustrating example operations for treating a subject suffering from a psychiatric disorder according to implementations described herein.
[0057] Figure 2 An example conditioning sequence delivered during neurocognitive training according to embodiments described herein is shown.
[0058] Figure 3 Another example conditioning sequence delivered during neurocognitive training according to embodiments described herein is shown.
[0059] Figure 4 Another example conditioning sequence delivered during neurocognitive training according to embodiments described herein is shown.
[0060] Figure 5 An example incidental task (ie, lexical decision) delivered during neurocognitive training according to embodiments described herein is shown.
[0061] Figure 6 Another example incidental task (ie, rapid selection) delivered during neurocognitive training according to implementations described herein is shown.
[0062] 7A to 7CAnother example conditioning sequence delivered during neurocognitive training according to embodiments described herein is shown. Fig. 7A An example user interface is shown. Figure 7B Example self-correlated and non-self-correlated stimulus pairs are shown. Figure 7C An example matrix is shown.
[0063] Figure 8 is an example computing device.
[0064] Fig. 9 Is a graph showing changes in depression severity scores (total Montgomery-Asberg Depression Rating Scale score) as a function of days post-infusion and treatment assignment in a randomized controlled trial of ketamine and automated self-association training (ASAT) [ketamine + active ASAT, n = 53; ketamine + mock ASAT, n = 50; saline + active ASAT, n = 51]. Line graphs represent means and error bars represent standard errors of the mean within each time point and treatment group.
[0065] Fig.10 Table S1 shows patients' and clinicians' guesses about treatment assignment as a function of true assignment.
[0066] FIG. 11A to FIG. 11D Table S2 shows adverse events. Fig.11A For patients treated with ketamine, adverse events were reported on the day of the infusion. Fig. 11B Adverse events reported by patients treated with ketamine after the infusion day. Fig. 11C Adverse events reported on the day of infusion for patients treated with normal saline. Fig.11D For patients treated with normal saline, adverse events were reported after the infusion day.
[0067] Fig.12 is Table S3 showing the robustness of the main findings in the main text when covariates are included in the model.
[0068] Fig.13 Shown are depression severity scores (Quick Inventory of Depressive Symptoms: Self-Report scale total score) as a function of days post-infusion and treatment assignment according to embodiments described herein. DETAILED DESCRIPTION
[0069] Unless otherwise limited, the meaning of all scientific and technological terms used herein is the same as that generally understood by those of ordinary skill in the art. Methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure. As used in this specification and in the accompanying claims, the singular forms "one", "a", "said" include multiple references unless the context clearly stipulates otherwise. The term "comprising" and its variants used herein are used synonymously with the term "including" and its variants, and are open, non-restrictive terms. The term "optional" or "optionally" used herein means that the features, events or situations described subsequently may or may not occur, and the description includes the situations in which the features, events or situations occur and the situations in which they do not occur. The range can be expressed as from "about" a specific value, and / or to "about" another specific value in this article. When expressing such a range, one aspect includes from a specific value and / or to another specific value. Similarly, when a value is expressed as an approximate value by using the prefix "about", it should be understood that the specific value forms another aspect. It will be understood that the endpoints of each of the ranges are significant both in relation to and independent of the other endpoint. Although the embodiments will be described with respect to the use of automated neurocognitive training to prolong remission of treatment-resistant depression following intravenous administration of ketamine, those skilled in the art will appreciate that the embodiments are not limited thereto but may be applicable to the use of automated neurocognitive training to prolong remission of treatment-resistant depression or other psychiatric disorders following administration of other drugs, compounds, or formulations.
[0070] As used herein, the term "about" or "approximately" when referring to a measurable value (such as an amount, a percentage, etc.) is intended to encompass variations of ±20%, ±10%, ±5%, or ±1% from the measured value.
[0071] "Administering" to a subject includes any route of introducing or delivering an agent to a subject. Administration can be by any suitable means for delivering the agent. Administration includes self-administration and administration by another person.
[0072] The term "subject" is defined herein to include animals such as mammals, including but not limited to primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, etc. In some embodiments, the subject is a human.
[0073] Reference now Figure 1, a flowchart showing an example operation for treating a subject (also referred to herein as a "patient") with a psychiatric disorder. The methods described herein have advantages over conventional methods, including, but not limited to, overcoming the clinical unreliability of cognitive training for patients with depression and / or overcoming the rapid dissipation of the effects of ketamine after a single administration. Other advantages of the methods described herein over the current standard of care for psychiatric disorders (such as depression) include: 1) having a rapid onset of beneficial effects (e.g., within 1 day); 2) being effective, requiring minimal time investment from the patient; 3) having a lasting effect of at least 3 months after a brief course of treatment; 4) being fully automated and portable (except for drug administration), making it scalable and easy to promote in a variety of clinical and non-clinical settings; 5) being not resource-intensive to administer, requiring minimal time investment from clinicians and medical professionals; and 6) being effective even in refractory patients who have not previously benefited from standard treatments. The methods described herein achieve these advantages by pairing the delivery of an antidepressant with the delivery of an automated neurocognitive training according to the protocol described herein. This automated neurocognitive training utilizes Pavlovian conditioning to promote positive implicit self-representation and self-worth. In addition, automated neurocognitive training can include tasks to enhance patient engagement in training. In some embodiments described herein, the mental disorder is depression. Optionally, the mental disorder is refractory depression, i.e., the patient is unable to respond to treatments such as antidepressants and / or psychotherapy. In other embodiments described herein, the mental disorder is suicidal behavior. It should be understood that depression and suicidal behavior are provided only as example mental disorders. The present disclosure contemplates that the mental disorder may be a condition other than depression and suicidal behavior, including other refractory mental disorders.
[0074] In step 102, a drug having an antidepressant effect is administered to a patient. As discussed above, the patient suffers from a psychiatric disorder, such as refractory depression. In some embodiments, the drug is a fast-acting antidepressant. As used herein, a fast-acting antidepressant has a therapeutic onset in a subject (e.g., a separation between an active drug and a control condition is observed in a randomized controlled trial) about 1 minute to 3 weeks after administration of the drug. This is in contrast to conventional (e.g., the vast majority of Food and Drug Administration (FDA) approved) antidepressants, which typically require 4 to 8 weeks to produce a therapeutic effect in a subject. Ketamine is an example fast-acting antidepressant. Ketamine is a well-known drug that is commonly used as an anesthetic. Intravenous ketamine has been administered to human subjects and has been shown to reduce symptoms of depression and / or reduce the desire for suicide. It should be understood that ketamine is provided only as an example fast-acting antidepressant. The present disclosure contemplates administering other rapid-acting antidepressants to patients, including but not limited to scopolamine and other NMDA receptor antagonists (see, e.g., Witkin JM, Martin AE, Golani LK, Xu NZ, Smith JL. Rapid-acting antidepressants. Adv Pharmacol. 2019; 86: 47-96. Doi: 10.1016 / bs.apha.2019.03.002. Epub 2019 April 24. PMID: 31378256), brendolone or lapastine. The present disclosure also contemplates administering other drugs with antidepressant effects to patients, including but not limited to zuranolone or hallucinogens (e.g., psilocybin, lysergic acid diethylamide, ayahuasca, 3,4-methylenedioxymethamphetamine (MDMA)).
[0075] In step 104, a neurocognitive training protocol is administered to the patient during a critical time period after the drug is administered. As used herein, the critical time period is a time period during which the drug is expected to rapidly proliferate synaptic contacts in the patient's brain. For example, the critical time period may optionally be between about 2 hours to about 14 days after the drug is administered. Optionally, the critical time period is between about 1 day to about 5 days after the drug is administered. It should be understood that the above-mentioned specific critical time periods are provided as examples only and may vary depending on the drug administered to the patient.
[0076] As described herein, the step of administering a neurocognitive training protocol to a patient includes delivering a plurality of automated neurocognitive training sessions to the patient using a computing device. The present disclosure contemplates that the computing device may be Figure 8. In addition, the computing device can be configured to generate content (e.g., including graphical display data) for the automated neurocognitive training session. For example, the computing device can be configured to generate content, which may include audio and / or visual content, for the conditioning sequence (discussed below). Optionally, the computing device also includes a display device, and the computing device is further configured to generate graphical data for each conditioning sequence and cause the graphical data to be displayed on the display device.
[0077] As described herein, the neurocognitive training protocol includes delivering multiple automated neurocognitive training sessions to the patient. The number of sessions can be between about 2 sessions and about 14 sessions, and optionally about 8 sessions. For example, in one embodiment described in the Examples below, eight automated neurocognitive training sessions are delivered to the patient. These eight sessions are performed twice a day over a period of four consecutive days. It was found that eight sessions of delivering automated neurocognitive training sessions twice a day for four consecutive days during the critical time period after drug administration can effectively treat depression. It should be understood that the number of sessions, the number of sessions per day, and the number of days are provided only as examples. The present disclosure contemplates delivering different numbers of automated neurocognitive training sessions to achieve a therapeutic effect in the patient. This includes changing the number of sessions per day and / or delivery over different numbers of continuous or non-continuous days.
[0078] In one example embodiment, the automated neurocognitive training session includes a first automated neurocognitive training session and a second automated neurocognitive training session delivered to the patient on the first day, and a third automated neurocognitive training session and a fourth automated neurocognitive training session delivered to the patient on the second day. The first day and the second day are different days, and are optionally continuous days or non-continuous days. In addition, the present disclosure contemplates delivering additional sessions to the patient on the first day and / or the second day, or optionally on a subsequent day (such as the third day, the fourth day, the fifth day, etc.). Optionally, the time period between the automated neurocognitive training sessions delivered on the same day is about 20 minutes or longer. The time interval between sessions (such as 20 minutes) is designed to promote "interval learning", which allows some brief forms of memory consolidation to occur between sessions, and based on the neuroscience of learning, it is believed to help retain information. It should be understood that the 20-minute time interval between sessions is provided only as an example. The present disclosure contemplates providing any time length between sessions to promote "interval learning" as described above. In addition, the duration of each automated neurocognitive training session is less than about 20 minutes, for example, between about 15 minutes and about 20 minutes. According to feedback, it was found that a session length of 15-20 minutes was efficient, effective, and avoided boredom and fatigue. It should be understood that the session length of 15-20 minutes is provided as an example only. The present disclosure contemplates the use of any session length that promotes effectiveness while achieving the above goals.
[0079] During automated neurocognitive training, multiple conditioning sequences are presented to the patient during the delivery of each automated neurocognitive training session. Optionally, in some embodiments described herein, each respective conditioning sequence includes a respective non-self-related stimulus and a respective self-related stimulus. Other conditioning sequences may include, but are not limited to, alternative treatment pairings targeting various mental health issues, such as pairings of stimuli (where approaching the stimulus or activity is desired) [e.g., feared (phobic) stimuli; currently avoided healthy and / or valuable activities or scenes; triggers associated with a future-oriented mindset] with respective positive stimuli; pairings of respective undesirable stimuli (where avoidance of the stimulus or activity is desired) (e.g., addiction-related craving triggers; self-harm-related triggers) with respective negative stimuli. Figure 2 An example conditioning sequence is shown. Figure 2 The conditioning sequence includes a non-self-relevant stimulus 202 (or "unconditioned stimulus (US)") that is associated with a positive trait (i.e., Figure 2 ), such as “sweet,” “attractive,” photos of smiling actors, etc., and a self-related stimulus 204 (or “conditioned stimulus (CS)”) that is associated with the patient (i.e., Figure 2 It should be understood that providing Figure 2 The equal sign shown in is merely to illustrate the concept of strengthening the association between the non-self-relevant stimulus 202 and the self-relevant stimulus 204 in the patient's brain. Figure 3 Another example conditioning sequence is shown in . Figure 3 The conditioning sequence includes a non-self-relevant stimulus 302, which is a random photo of a smiling person (i.e., a positive trait), and a self-relevant stimulus 304, which is a photo of the subject. Such a conditioning sequence is designed to utilize Pavlovian conditioning to promote positive implicit self-representations and self-worth. It should be understood that the Figure 2 and Figure 3 The stimuli shown and described are provided as examples only. For example, the present disclosure contemplates that in some embodiments, the non-self-related stimuli and / or the self-related stimuli are auditory stimuli. Alternatively or in addition, in some embodiments, the non-self-related stimuli and / or the self-related stimuli are visual stimuli. Optionally, the self-related stimuli for each respective conditioning sequence include sounds, images, or words associated with the patient. Optionally, the sound images or words can have positive meanings, or the sound images or words can have life-affirming meanings.
[0080] Optionally, in some embodiments, one or more of the plurality of conditioning sequences comprises subthreshold presentation of a non-self-relevant stimulus or a self-relevant stimulus. Alternatively or additionally, in some embodiments, one or more of the plurality of conditioning sequences comprises suprathreshold presentation of a non-self-relevant stimulus or a self-relevant stimulus. Figure 4 , where a non-self-related stimulus 402 (i.e., the word "OK") and a self-related stimulus 404 (i.e., the word "I") are presented in a sequence. For example, in some embodiments, the non-self-related stimulus 402 and the self-related stimulus 404 are presented subthreshold in the sequence. Subthreshold stimuli are below the patient's threshold of conscious perception (e.g., 17 milliseconds (ms)). In other embodiments, the non-self-related stimulus 402 and the self-related stimulus 404 are presented suprathreshold in the sequence. Suprathreshold stimuli are above the patient's threshold of conscious perception (e.g., presented at 500ms). It should be understood that Figure 4 The respective durations of subthreshold and suprathreshold presentations shown in are provided as examples only. The present disclosure contemplates that the respective durations may be any duration below the threshold of consciousness (i.e., subthreshold) or above the threshold of consciousness (i.e., suprathreshold), for example, subthreshold (e.g., about 12ms stimulation) or suprathreshold (e.g., >250ms stimulation).
[0081] Alternatively or additionally, in some embodiments, each respective conditioning sequence further comprises a task, wherein the task is presented to the patient after or in conjunction with presentation of the respective non-self-relevant and self-relevant stimulus pair. Figure 4 , where the patient is prompted to respond to a random stimulus 406 (i.e., the word string "ozgdpyc") whether it begins with a vowel or a non-vowel. The task is presented after the presentation of the stimulus pairs (i.e., the non-self-relevant stimulus 402 and the self-relevant stimulus 404 pair). In another embodiment, the task (lexical decision task) is performed after the non-self-relevant stimulus (e.g., Figure 4 The task begins with the presentation time of a non-self-relevant stimulus 402 in the image, and the subject responds to the non-self-relevant stimulus to indicate whether the non-self-relevant stimulus includes a real word or a non-word (e.g., a random string of letters). This task can enhance patient engagement in automated neurocognitive training, which promotes semantic and visual processing of stimuli (e.g., conditioning sequences designed to utilize Pavlovian conditioning to promote positive implicit self-representations and self-worth). It should be understood that Figure 4 The tasks described are provided as examples only. The present disclosure contemplates presenting another incidental task, including but not limited to a lexical decision task or a rapid mouse click task. Figure 5 Another example lexical decision task is shown in , in which patients are prompted to label words and non-words (ie, random strings of characters), where the words in the task are the non-self-relevant stimuli involved in the conditioning sequence. Figure 6 An example mouse clicking task is shown in FIG. 6 , in which a patient is prompted to click / tap as quickly as possible on a photo 602. The photo 602 (self-relevant stimulus) moves from one quadrant to another over time. After the subject's click / tap, a non-self-relevant stimulus ( Figure 6 ). An example non-self-relevant stimulus is an image of a stranger with a smiling face.
[0082] Alternatively or additionally, in some embodiments, the respective non-self-relevant stimuli and the respective self-relevant stimuli for each respective conditioning sequence are included in an nxm matrix comprising a plurality of visual stimuli, where n and m are positive integers. 7A to 7C Specifically, Figure 7C 7 shows a matrix 710 of visual stimuli. In this example, the matrix 710 includes 2 rows and 4 columns of visual stimuli (e.g., words or pictures). Figure 7C Where n=2 and m=4. It should be understood that the size of matrix 710 is provided only as an example and may have another size. Prior to presenting matrix 710, the subject is presented with a plurality of matched pairs of visual stimuli, including at least one pair of non-self-related and self-related stimuli. Figure 7B Specifically, Figure 7B "Pair 1" in FIG. 7 is a non-self-relevant stimulus 702a (ie, a random photo of a smiling person, which is a positive trait) and a self-relevant stimulus 704a (ie, a photo of the subject). Figure 7B "Pair 2" in FIG. 1 is a non-self-relevant stimulus 702b (i.e., a life-affirming or life-related photo) and a self-relevant stimulus 704b (i.e., another photo of the subject). "Pair 3" does not include a self-relevant stimulus and is provided to increase the variety and difficulty of the task presentation. During automated neurocognitive training, and as Figure 7C As shown, a plurality of visual stimulus matrices including matrix 710 are presented to the subject, and the subject is prompted to respond to matching non-self-related and self-related stimuli (e.g., Figure 7B Correct selection 720 of non-self-relevant stimulus 702a and self-relevant stimulus 704a) is shown.
[0083] Example Method
[0084] The therapeutic methods and computer-implemented methods for administering neurocognitive training described herein achieve advantages over conventional techniques by pairing the delivery of antidepressants with the delivery of automated neurocognitive training. Specifically, the automated neurocognitive training protocols described herein utilize Pavlovian conditioning to promote positive implicit self-representations and self-worth. Such protocols are designed to achieve positive results. In addition, automated neurocognitive training can include tasks to enhance the patient's participation in the training.
[0085] Example methods for treating patients with mental disorders are described herein. The present disclosure contemplates that the logical operations of the methods described below may be performed using a computing device (e.g., at least one processor and a memory such as a computer program product). Figure 8 The method comprises administering a drug having an antidepressant effect to the patient, and administering a neurocognitive training protocol to the patient during a critical time period after the administration of the drug. In addition, the step of administering the neurocognitive training protocol to the patient comprises delivering a plurality of automated neurocognitive training sessions to the patient using the computing device. During the delivery of each automated neurocognitive training session, a plurality of conditioning sequences are presented to the patient, wherein each respective conditioning sequence comprises a respective non-self-relevant stimulus and a respective self-relevant stimulus.
[0086] Described herein are example computer-implemented methods for administering a neurocognitive training protocol to a patient with a psychiatric disorder. The present disclosure contemplates that the logical operations of the methods described below may be performed using a computing device (e.g., at least one processor and a memory such as a computer program). Figure 8 The method comprises delivering a plurality of automated neurocognitive training sessions to the patient. In addition, during the delivery of each automated neurocognitive training session, a plurality of conditioning sequences are presented to the patient, wherein each respective conditioning sequence comprises a respective non-self-relevant stimulus and a respective self-relevant stimulus.
[0087] Another example method for treating a patient with a mental disorder is described herein. The present disclosure contemplates that the logical operations of the method described below may be performed using a computing device (e.g., at least one processor and a memory such as Figure 8The method comprises administering a drug having an antidepressant effect to the patient, and administering a neurocognitive training protocol to the patient during a critical time period after the administration of the drug. In addition, the step of administering the neurocognitive training protocol to the patient comprises delivering a plurality of automated neurocognitive training sessions to the patient using a computing device. Each respective automated neurocognitive training session comprises presenting an nxm matrix comprising a plurality of visual stimuli to the patient, and receiving the patient's selection of a first matching pair of non-self-related and self-related visual stimuli. The plurality of visual stimuli comprises a first matching pair of non-self-related and self-related visual stimuli. In addition, in some embodiments, each respective automated neurocognitive training session further comprises presenting a second matching pair of non-self-related and self-related visual stimuli to the patient, and presenting a task to the patient after presenting the second matching pair of non-self-related and self-related visual stimuli. Optionally, each respective automated neurocognitive training session further comprises presenting a self-related visual stimulus to the patient, presenting a task to the patient after presenting the self-related stimulus, and presenting a positive self-related visual stimulus after the patient successfully completes the task.
[0088] Another example method for treating a patient with a mental disorder is described herein. The present disclosure contemplates that the logical operations of the method described below may be performed using a computing device (e.g., at least one processor and a memory such as Figure 8 The method includes administering a drug having an antidepressant effect to the patient; and administering a neurocognitive training protocol to the patient during a key time period after the administration of the drug. The step of administering the neurocognitive training protocol to the patient includes delivering a plurality of automated neurocognitive training sessions to the patient using the computing device, wherein a plurality of conditioning sequences are presented to the patient during the delivery of each automated neurocognitive training session.
[0089] This document describes an example method for conditioning therapeutic associations in patients. The present disclosure contemplates that the logical operations of the methods described below may be performed using a computing device (e.g., at least one processor and a memory such as a computer program product). Figure 8 The method includes: administering a neuroplasticity enhancing treatment to a patient; and administering a neurocognitive training protocol to the patient during a critical time period after the administration of the neuroplasticity enhancing treatment. The step of administering the neurocognitive training protocol to the patient includes delivering one or more conditioning sequences configured for conditioning a therapeutic association to the patient using a computing device. Non-limiting examples of combinations of neuroplasticity enhancing treatments and neurocognitive training protocols are described below. The present disclosure contemplates that any of the example neuroplasticity enhancing treatments can be combined with any of the example neurocognitive training protocols in order to condition a therapeutic association.
[0090] In some embodiments, the neuroplasticity enhancing treatment is a neuromodulatory intervention. Neuromodulatory interventions include non-pharmacological interventions such as transcranial magnetic stimulation, transcranial direct current stimulation, transcranial focused ultrasound, or other neuromodulatory manipulations. Alternatively or in addition, in other embodiments, the neuroplasticity enhancing treatment is a drug. As described herein, the drug can be an antidepressant, and optionally a fast-acting antidepressant such as ketamine. It should be understood that antidepressants are provided only as examples, and other drugs or neuroplasticity enhancers can be delivered.
[0091] In addition, in some embodiments, the neurocognitive training protocol includes delivering an automated neurocognitive training session as described herein, for example, a plurality of conditioning sequences that pair self-related with non-self-related stimuli. In other embodiments, the neurocognitive training protocol includes delivering an automated neurocognitive training session, which may include, but is not limited to, treatment pairings targeting various mental health problems. This treatment pairing may include stimulation (where approaching the stimulation or activity is desired) [e.g., feared (phobic) stimulation; currently avoided healthy and / or valuable activities or scenes; triggers associated with a future-oriented mindset] and respective positive stimulations. This neurocognitive training can be used for conditioning training to approach feared (phobic) stimulation, currently avoided healthy and / or valuable activities or scenes, or triggers associated with a future-oriented mindset. Alternatively, this treatment pairing may include undesirable stimulation (where avoidance of the stimulation or activity is desired) (e.g., addiction-related craving triggers; self-harm-related triggers) and respective negative stimulations. This neurocognitive training can be used for conditioning training to resist or avoid the increase of craving (addiction-related), self-harm-related or other undesirable triggers.
[0092] Example computing device
[0093] It should be understood that the logical operations described herein with respect to the various figures may be implemented as (1) on a computing device (e.g., Figure 8 The logical operations discussed herein are referred to as (i) a series of computer-implemented actions or program modules (i.e., software) running on a computing device described in (a), (b) interconnected machine logic circuits or circuit modules (i.e., hardware) within a computing device, and / or (c) a combination of software and hardware of a computing device. Therefore, the logical operations discussed herein are not limited to any specific combination of hardware and software. The implementation is a matter of choice depending on the performance and other requirements of the computing device. Therefore, the logical operations described herein are variously referred to as operations, structural devices, actions, or modules. These operations, structural devices, actions, and modules may be implemented in software, in firmware, in dedicated digital logic, and any combination thereof. It should also be understood that more or fewer operations than shown in the figures and described herein may be performed. The operations may also be performed in an order different from the order described herein.
[0094] refer to Figure 8 , an example computing device 800 on which the methods described herein can be implemented is shown. It should be understood that the example computing device 800 is only an example of a suitable computing environment on which the methods described herein can be implemented. Optionally, the computing device 800 can be a well-known computing system, including but not limited to a personal computer, a server, a handheld or laptop device, a multiprocessor system, a microprocessor-based system, a network personal computer (PC), a minicomputer, a mainframe computer, an embedded system and / or a distributed computing environment including a plurality of any of the above systems or devices. A distributed computing environment enables remote computing devices connected to a communication network or other data transmission medium to perform various tasks. In a distributed computing environment, program modules, applications and other data can be stored on local and / or remote computer storage media.
[0095] In its most basic configuration, computing device 800 typically includes at least one processing unit 806 and system memory 804. Depending on the exact configuration and type of computing device, system memory 804 may be volatile (such as random access memory (RAM)), non-volatile (such as read-only memory (ROM), flash memory, etc.), or some combination of the two. Figure 8 800 is shown by dashed line 802. Processing unit 806 may be a standard programmable processor that performs the arithmetic and logic operations necessary for the operation of computing device 800. Computing device 800 may also include a bus or other communication mechanism for communicating information between the various components of computing device 800.
[0096] The computing device 800 may have additional features / functionality. For example, the computing device 800 may include additional storage devices, such as a removable storage device 808 and a non-removable storage device 810, including but not limited to a disk or optical disk or tape. The computing device 800 may also contain a network connection 816 that allows the device to communicate with other devices. The computing device 800 may also have an input device 814, such as a keyboard, a mouse, a touch screen, etc. Output devices 812 such as a display, a speaker, a printer, etc. may also be included. Additional devices may be connected to the bus to facilitate data communication between the components of the computing device 800. All of these devices are well known in the art and need not be discussed in detail here.
[0097] Processing unit 806 can be configured to execute program code encoded in a tangible computer-readable medium. Tangible computer-readable medium refers to any medium that can provide data that causes computing device 800 (i.e., machine) to operate in a specific manner. Various computer-readable media can be used to provide instructions to processing unit 806 for execution. Example tangible computer-readable media include, but are not limited to, volatile media, non-volatile media, removable media, and non-removable media, which implement information storage in any method or technology, such as computer-readable instructions, data structures, program modules, or other data. System memory 804, removable storage device 808, and non-removable storage device 810 are all examples of tangible computer storage media. Example tangible computer-readable recording media include, but are not limited to, integrated circuits (e.g., field programmable gate arrays or application-specific integrated circuits), hard disks, optical disks, magneto-optical disks, floppy disks, magnetic tapes, holographic storage media, solid-state devices, RAM, ROM, electrically erasable programmable read-only memory (EEPROM), flash memory or other memory technology, CD-ROM, digital versatile disk (DVD) or other optical storage devices, cassettes, magnetic tapes, magnetic disk storage devices or other magnetic storage devices.
[0098] In one example implementation, processing unit 806 may execute program code stored in system memory 804. For example, a bus may transfer data to system memory 804, from which processing unit 806 receives and executes instructions. Data received by system memory 804 may optionally be stored on removable storage device 808 or non-removable storage device 810 before or after execution by processing unit 806.
[0099] It should be understood that the various techniques described herein can be implemented in combination with hardware or software, or in combination with their combination in appropriate circumstances. Thus, the method and apparatus of the currently disclosed subject matter or some aspects or parts thereof can take the form of program code (i.e., instruction) embodied in tangible media such as floppy disks, CD-ROMs, hard disk drives, or any other machine-readable storage medium, wherein, when the program code is loaded into a machine (such as a computing device) and executed by it, the machine becomes a device for practicing the currently disclosed subject matter. In the case where the program code is executed on a programmable computer, the computing device generally includes a processor, a storage medium (including volatile and non-volatile memory and / or storage element) readable by the processor, at least one input device, and at least one output device. One or more programs can be implemented or utilized in conjunction with the process described in the currently disclosed subject matter, for example, by using an application programming interface (API), reusable controls, etc. Such a program can be implemented with a high-level procedural or object-oriented programming language to communicate with a computer system. However, if necessary, the program can be implemented with an assembly or machine language. In any case, the language can be a compiled language or an interpreted language, and it can be combined with hardware implementation.
[0100] Example
[0101] The following examples are presented to provide a person of ordinary skill in the art with a complete disclosure and description of how to prepare and evaluate the compounds, compositions, articles, devices and / or methods claimed herein, and are intended to be purely exemplary and not intended to limit the present disclosure. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperatures, etc.), but some errors and deviations should be considered. Unless otherwise indicated, parts are parts by weight, temperatures are ° C or ambient temperature, and pressures are atmospheric or near atmospheric.
[0102] Example 1
[0103] A randomized controlled trial was completed to test whether reinforcing ("conditioning") beneficial, positive beliefs about the self via fully automated neurocognitive training (NT) software could prolong and / or enhance rapid mood relief during the "window of opportunity" following ketamine infusion. Automated NT is also referred to herein as automated self-association training (ASAT). A critical gap in previous efforts to develop NT treatments, which this study fills, is to co-initiate neurocognitive training during the critical clinical window of opportunity (immediately following ketamine infusion) when mood improvements and increased neuroplasticity are expected to occur in order to consolidate beneficial processing patterns and augment and prolong the rapid mood effects of ketamine.
[0104] Results from this double-blind, randomized, controlled trial confirmed the hypothesis. Ketamine rapidly reduced depression scores 24 hours after infusion (relative to saline control infusion) in patients with treatment-resistant depression (i.e., patients who had not previously responded to first-line antidepressants). A brief (2.5 hours total, eight 20-minute sessions over four days), fully automated, computer-based NT intervention (designed for conditioning to establish positive self-representations) or a sham / placebo version of NT was then initiated. During the 30-day acute postinfusion phase, the combination of ketamine + active NT ( Fig. 9 Ketamine + active ASAT) relative to saline + NT ( Fig. 9 In contrast, ketamine plus NT mimetic ( Fig. 9 Ketamine + mock ASAT in the NT group (in the NT group) produced an initial reduction in depression that linearly attenuated over a 30-day window, becoming nonsignificant on post-infusion day 12. In ongoing naturalistic follow-up, the ketamine + NT group showed sustained benefits on self-reported depression 3 months after infusion (see Example 9).
[0105] In another ongoing randomized controlled trial, this synergistic combination (ketamine + computer-based NT) is being tested in hospitalized patients immediately after a suicide attempt in an effort to prevent future suicidal ideation, reattempts, and completed suicide in this very high-risk group.
[0106] In conclusion, brief synergistic treatment, combining ketamine infusion with fully automated cognitive training software, rapidly brought relief and then effectively prolonged relief in patients with refractory depression by exploiting a window of opportunity via a safe, low-cost, portable technology. Given that intravenous ketamine is very common and widely used in hospital settings as well as specialized community clinics worldwide; and that the fully automated cognitive training software is extremely effective, simple, easy, and feasible to administer and complete both in clinical settings and in patients' homes, this treatment strategy has a wide range of potential applications.
[0107] Example 2
[0108] introduction
[0109] Depression is one of the most common and costly mental health disorders [Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6): 617-27], and its public disease burden is staggering [Kessler RC: The global burden of anxiety and mood disorders: putting the European Study of the Epidemiology of Mental Disorders (ESEMeD) findings into perspective. J Clin Psychiatry. 2007; 68 Suppl 2: 10-9]. Although effective treatments have been available for decades, remission rates are low, relapse rates are high, and the prevalence of the disorder remains remarkably consistent or increases, with only 12.7% of patients receiving minimal treatment [Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC: Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6): 629-40]. In recent years, two potential breakthroughs have raised hopes for a paradigm shift in the clinical management of this disabling disorder.First, fast-acting drug preparations—particularly intravenous ketamine [Xu Y, Hackett M, Carter G, Loo C, Galvez V, Glozier N, Glue P, Lapidus K, McGirr A, Somogyi AA, Mitchell PB, Rodgers A: Effects of low-dose and very low-dose dose ketamine among patients with major depression: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2015; Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB, Treatments APA CoRTFoNBa: Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. Am J Psychiatry. 2015; 172(10):950-66; Caddy C, Amit BH, McCloud TL, Rendell JM, Furukawa TA, McShane R, Hawton K, Cipriani A: Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev. 2015; Sep 23(9): CD011612]—shows promise in significantly reducing symptoms within 2-24 hours, overcoming the slow response to conventional therapies (e.g., 4-6 week delays), which prolongs distress, creates nonadherence issues, and fails to address urgent clinical needs (e.g., suicidal and other psychiatric crises).Second, intervention development has increasingly sought to leverage technology to increase patient access, reduce costs, and minimize adverse outcomes through the use of automated, computer-based algorithms [Mohr DC, Burns MN, Schueller SM, Clarke G, Klinkman M: Behavioral intervention technologies: evidence review and recommendations for future research in mental health. Gen Hosp Psychiatry. 2013; 35(4): 332-8]. Over the past decade, there has been increasing interest in automated, mechanical NT treatments designed to directly modulate affective processing patterns to reduce symptoms [Siegle GJ, Price RB, Jones N, Ghinassi F, Painter T, Thase ME: You gotta work at it: Pupillary indices of task focus are prognostic for response to aneurocognitive intervention for depression. Clin Psychol Sci. 2014; 2(4): 455-71]; however, despite showing promise, clinical efficacy remains less reliable, particularly in patients with acute depression [Mogoase C, David D, Koster EHW: Clinical Efficacy of Attentional Bias Modification Procedures: An Updated Meta-analysis. J Clin Psychol. 2014; 70: 1133-57; Motter JN, Pimontel MA, Rindskopf D, Devanand DP, Doraiswamy PM, Sneed JR: Computerized cognitive training and functional recovery in major depressive disorder: Ameta-analysis. J Affect Disord. 2016; 189: 184-91]. The study described below aimed to synergistically combine the benefits of these two approaches.
[0110] The rapidity of ketamine's action offers the promise of a breakthrough in the management of depression, but this promise has yet to be realized. The rapid dissipation of ketamine's effects [Walter M, Li S, Demenescu LR: Multistage drug effects of ketamine in the treatment of major depression. Eur Arch Psychiatry Clin Neurosci. 2014; 264 Suppl 1: S55-65], as well as substantial concerns about the safety and feasibility of repeated infusions [Schatzberg AF: A word to the wise about ketamine. Am J Psychiatry. 2014; 171(3): 262-4; Price RB: From Mice to Men: Can Ketamine Enhance Resilience to Stress? Biol Psychiatry. 2016; 79(9): e57-9], limit ketamine's clinical impact. Although substantial progress has recently been made in understanding the molecular mechanisms of ketamine's actions [Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KS, Fang Y, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA, Jr., Gould TD: NMDAR inhibition-independent antidepressant actions of ketaminemetabolites. Nature. 2016; 533(7604): 481-6; Malinow R: Depression: Ketamine steps out of the darkness. Nature. 2016; 533(7604): 477-8] and in developing strategies to pharmacologically prolong these effects, their translation into safe, effective novel pharmacologies may be slow and uncertain.Furthermore, long-term pharmacological intervention is unlikely to be beneficial, feasible, or attractive to every patient [Bockting CL, ten Doesschate MC, Spijker J, Spinhoven P, Koeter MW, Schene AH, group Ds: Continuation and maintenance use of antidepressants in recurrent depression. Psychother Psychosom. 2008; 77(1): 17-26].Most patients (e.g., up to 91% of patients with depression who participate in drug trials [Steidtmann D, Manber R, Arnow BA, Klein DN, Markowitz JC, Rothbaum BO, Thase ME, Kocsis JH: Patient treatment preference as a predictor of response and attrition in treatment for chronic depression. Depress Anxiety. 2012; 29(10):896-905]) consistently express a preference for behavioral therapy or combined behavioral / drug therapy [Huijbers MJ, Spinhoven P, van Schaik DJ, Nolen WA, Speckens AE: Patients with apreference for medication do equally well in mindfulness-based cognitive therapy for recurrent depression as those preferring mindfulness. J Affect Disord. 2016; 195:32-; van Schaik DJ, Klijn AF, van Hout HP, van Marwijk HW, Beekman AT, de Haan M, van Dyck R: Patients' preferences in the treatment of depressive disorder in primary care. Gen Hosp Psychiatry. 2004; 26(3): 184-9], in part reflecting the belief that such treatment will introduce new learning that will address core problems and bring about lasting change [van Schaik DJ, Klijn AF, van Hout HP, van Marwijk HW, Beekman AT, de Haan M, van Dyck R: Patients' preferences in the treatment of depressive disorder in primary care. Gen Hosp Psychiatry. 2004; 26(3): 184-9].Long-term maintenance of an antidepressant pharmacological regimen is challenging due to patient discontinuation [Bockting CL, ten Doesschate MC, Spijker J, Spinhoven P, Koeter MW, Schene AH, group Ds: Continuation and maintenance use of antidepressants in recurrent depression. Psychother Psychosom. 2008; 77(1): 17-26] and the scarcity of follow-up opportunities in community practice [Simon GE, Von Korff M, Rutter CM, Peterson Da: Treatment process and outcomes for managed care patients receiving new antidepressant prescriptions from psychiatrists and primary care physicians. Arch Gen Psychiatry. 2001; 58: 395-401].
[0111] Ketamine is thought to reverse the molecular features of depression at the molecular level through synaptogenesis and neuroplasticity effects [Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KS, Fang Y, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA, Jr., Gould TD: NMDARinhibition-independent antidepressant actions of ketaminemetabolites. Nature. 2016; 533(7604): 481-6; Abdallah CG, Sanacora G, Duman RS, Krystal JH: Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med. 2015; 66: 509-23; Duman RS, Aghajanian GK, Sanacora G, Krystal JH: Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016; 22(3): 238-49].Based on previous work, it is hypothesized [Price RB, Duman R: Neuroplasticity in cognitive and psychological mechanisms of depression: An integrative model. Mol Psychiatry. 2020; 25(3): 530-43; Wilkinson ST, Holtzheimer PE, Gao S, Kirwin DS, Price RB: Leveraging Neuroplasticity to Enhance Adaptive Learning: The Potential for Synergistic Somatic-Behavioral Treatment Combinations to Improve Clinical Outcomes in Depression. 2019; 85(6): 454-65] that these molecular effects may produce corresponding neurocognitive shifts, for which behavioral learning-based approaches could be used—for example, by strengthening adaptive cognitive patterns with neurocognitive training (NT) to prolong rapid mood relief during the window of opportunity. This study was designed to synergistically prime NT during a critical clinical window of opportunity (i.e., 1 day after ketamine infusion, when affective euthymia and enhanced plasticity are expected) in order to consolidate beneficial processing patterns and prolong the rapid mood effects of ketamine.
[0112] The growing trend of creating synergistic biobehavioral approaches for the management of psychosis, including ketamine [Dakwar E, Levin FR, Hart CL, Basaraba CN, Choi CJ, Pavlicova M, Nunes EV: A single ketamine infusion combined with motivational enhancement therapy for alcohol usedisorder: A randomized, midazolam-controlled pilot trial. Am J Psychiatry. 2020; 177: 125-33; Dakwar E, Nunes EV, Hart CL, Foltin RW, Mathew SJ, Carpenter KM, Choi CJJ, Basaraba CN, Pavlicova M, Levin FR: A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. Am J Psychiatry.2019:appiajp201918101123; WilkinsonST, Rhee TG, Joormann J, Webler R, Ortiz Lopez M, Kitay B, Fasula M, Elder C, FentonL, Sanacora G: Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial. Psychother Psychosom.2021; 90(5): 318-27] and other "psychoplasticity-generating" drugs [Vargas MV, Meyer R, Avanes AA, Rus M, Olson DE: Psychedelics and Other Psychoplastogens for Treating Mental Illness. Front Psychiatry.2021;12:727117]), this study was designed to push the boundaries of how fast-acting antidepressant agents can be used clinically as short-term cognitive flexibility enhancers to promote lasting learning that is counterproductive to the depressive state. Ketamine infusions were used as the first step in a treatment protocol designed to promote rapid and lasting relief while leveraging the potential of technology for low cost, portability, safety, and ease of dissemination of interventions. The results of studies showing that behavioral therapy can prevent relapse of depression even in the absence of ongoing care [Bockting CL, ten Doesschate MC, Spijker J, Spinhoven P, Koeter MW, Schene AH, group Ds: Continuation and maintenance use of antidepressants in recurrent depression. Psychother Psychosom. 2008; 77(1): 17-26; Bockting CL, Schene AH, Spinhoven P, Koeter MW, Wouters LF, Huyser J, Kamphuis JH: Preventing relapse / recurrence in recurrent depression with cognitive therapy: a randomized controlled trial. J Consult Clin Psychol. 2005; 73(4): 647-57; Hollon SD, Stewart MO, Strunk D: Enduring effects for cognitive behavior therapy in the treatment of depression and anxiety. 2006; 57: 285-315; Hollon SD, DeRubeis RJ, Shelton RC, Amsterdam JD, Salomon RM, O'Reardon JP, Lovett ML, YoungPR, Haman KL, Freeman BB, Gallop R: Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch GenPsychiatry.2006;62:417-22] and preliminary evidence that brief NT approaches can also have lasting and clinically meaningful effects [Siegle GJ, Price RB, Jones N, Ghinassi F, Painter T, Thase ME: You gotta work at it: Pupillary indices of task focus are prognostic for response to a neurocognitive intervention for depression. Clin Psychol Sci. 2014;2(4):455-71; Franklin JC, Fox KR, Franklin CR, Kleiman EM, Ribeiro JD, Jaroszewski AC, Hooley JM, Nock MK: A brief mobile app reduces nonsuicidal and suicidal self-injury: Evidence from three randomized controlled trials. J Consult Clin Psychol. 2016; 84(6): 544-57], it was hypothesized that introducing and promoting new learning during the ketamine-induced window of opportunity would provide an effective pathway for rapid and lasting relief. In this groundbreaking study, an active / active combination of ketamine + automated neurocognitive training (NT) as described herein was compared to a control condition that included each intervention component lacking the other (i.e., saline + active NT; ketamine + mock NT) in a randomized, double-blind, parallel-group design. This enabled direct testing of the hypothesized synergy between ketamine and NT in an attempt to produce both rapid and lasting antidepressant effects. .
[0113] Example 3
[0114] method
[0115] Participants. To achieve the initial enrollment goal of n = 150 patients, n = 154 patients were enrolled and randomized, and enrollment continued until a final sample was obtained, which included the full goal of n = 150 patients who completed at least: (1) the infusion day, (2) the 24-hour assessment visit, and (3) ≥ 75% of the expected cognitive training (active or simulated NT) visits. All n = 154 randomly assigned patients were included in the reported intention-to-treat analyses. Specifically, 154 adult patients (aged 18-60 years) who reported moderate to severe depression levels [Montgomery-Asberg Depression Rating Scale (MADRS; [Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134: 382-9] score ≥ 25] and self-reported self-esteem below standard levels [i.e., on the "self" subscale of the Cognitive Triad Scale [Beckham EE, Leber WR, Watkins JT, Boyer JL, Cook JB: Development of an instrument to measure Beck's cognitive triad: the Cognitive Triad Inventory. J Consult Clin Psychol. 1986; 54(4): 566-7]] were recruited and randomly assigned. cognition:thecognitive triad inventory.J Clin Psycho.1995;51(5):603-9;Possel P:CognitiveTriad Inventory(CTI):psychometric properties and factor structure of theGerman translation.J Behav Ther Exp Psychiatry.2009;40(2):240-7] and / or a score on the Rosenberg Self-Esteem Scale that was 1 standard deviation above the normative mean], and at least one failed and adequate trial of an FDA-approved antidepressant during the current depressive episode (based on the Antidepressant Treatment Response Questionnaire; ATRQ [Chandler GM, Iosifescu DV, Pollack MH, Targum SD, Fava M: RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther. 2010;16(5):322-5]). Any existing depression treatment regimen needed to have been started ≥4 weeks prior to screening and maintained stably throughout the trial. Sample characteristics see. Fig.10 , Table S1 and Examples 6-8 below.
[0116] In order to achieve the initial recruitment target of 150 patient samples, this study recruited and randomly assigned 154 patients, continued to recruit until the final sample was obtained, including the full target of 150 patients who completed at least the following: infusion day, 24-hour assessment visit, and ≥75% of the expected training (active or simulated ASAT) visits, and thus deemed to have accepted their ASAT allocation. Except for two participants, all participants who exceeded the 75% threshold of their ASAT allocation received the expected ASAT visits of complete eight session doses according to the protocol (for all the completers who followed the protocol for all assigned ASAT sessions N=148). Thus, 96% of the randomly assigned participants fully complied with all intervention sessions, and delivered 97% of all expected ASAT sessions.
[0117] A three-group study design was chosen so that all available resources were allocated to the active / active (ketamine+ASAT) treatment group and two key comparison groups compared thereto, each containing each intervention component without the other, which was a conservative test of the combined effect of the active / active biobehavioral intervention. In order to maximize the statistical power of these more conservative and key contrasts, the inactive / inactive (non-treatment) group was abandoned. The a priori power analysis was based on the primary interest in clinically significant moderate (or larger) effects. The target sample size was selected to achieve 80% power to detect a moderate effect, based on a comparison of 100 ketamine patients and 50 saline patients during the infusion phase (d≥0.49 and r≥0.31, using α=0.05), and based on a comparison of 50 patients in each of the ketamine+ASAT condition, ketamine+sham condition, and saline+ASAT condition during the ASAT phase, where an effect of d≥0.57 could be detected with 80% power (using α=0.05). The power of the main mixed-effects analysis comparing treatment groups (which would increase with additional repeated measures) was expected to be higher than the power of these simplified single-point contrasts, making these power calculations conservative.
[0118] Assessment Timeline. An experienced master's level clinical rater (CRS) administered the MADRS, the pre-specified primary endpoint of the study, throughout the acute (30-day) study period to assess overall depression severity. This measurement was repeated at screening (for eligibility determination only), pre-infusion baseline (1 hour before infusion; the clinical rater then left and was not present during any intervention procedures), 24 hours after infusion (before the first active / simulated NT session), 5 days, 12 days, 21 days, and 30 days. A 1-year exploratory naturalistic follow-up is still ongoing, which utilizes remote assessments obtained strictly through a unique self-report symptom scale (QIDS-SR [Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB: The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C) and Self-Report (QIDS-SR): A Psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003; 54: 573-83]), and therefore these data are not included in this report. This study also envisions the inclusion and analysis of neurocognitive (e.g., neuroimaging; performance-based) assessments of the effects of ketamine. Adequacy of blinding of infusion and NT assignment was assessed by both patients and raters by self-report using a 0-100 sliding scale (0 = definitely placebo / sham; 50 = I don't know; 100 = definitely ketamine / active) 30 days after infusion.
[0119] Intervention. A randomization table using 3 or 6 permuted blocks stratified by (1) biological sex at birth and (2) moderate versus severe treatment resistance (severe = receiving ≥3 FDA-approved antidepressant trials during the episode according to the ATRQ) was generated by an independent statistical consultant at the start of the study and maintained by the study pharmacist, who communicated the NT assignment (but not the infusion assignment) to the single research staff member assigned to the patient at randomization. The single staff member was responsible for opening the correct computer program to deliver the NT session to the patient but was not involved in nor on-site for any outcome assessments. Blinding of all other study personnel was maintained until after the final patient's Day 30 assessment was completed.
[0120] Infusion. Participants were randomized 2:1 to receive either a ketamine infusion (0.5 mg / kg over 40 minutes) or a saline infusion (50 ml of 0.9% sodium chloride over 40 minutes). All infusions were performed by blinded licensed nurses in a medical hospital setting with an associated ACLS-certified team and supervised by a blinded research physician (RHH), with safety / adverse event monitoring continuing for up to 4 hours post-infusion. Adverse events ( FIG. 11A to FIG. 11D , Table S2) were mild to moderate, limited in duration, and consistent with the safety profile described in numerous previous trials using the same infusion schedule.
[0121] Cognitive training. Drawing on previous work that used "evaluative conditioning" to influence participants' preferences and "likings" [De Houwer J, Thomas S, Baeyens F: Associative learning of likes and dislikes: a review of 25 years of research on human evaluative conditioning. Psychol Bull. 2001; 127(6): 853-69; Martijn MV, Roefs A, Huijding J, Jansen A: Increasing body satisfaction of body concerned women through evaluative conditioning using social stimuli. Health Psychol. 2010; 29(5): 514-20], an active NT (also referred to herein as an active ASAT) was designed to utilize Pavlovian conditioning to promote positive implicit self-representations and self-worth. In each of eight 15-20 minute sessions (delivered twice daily for 4 consecutive days with an interval of ≥20 minutes between sessions, starting one day after infusion and after a 24-hour post-infusion assessment), word and image stimulus pairs were presented, including suprathreshold (≥250ms) and subthreshold (12ms) presentations, to practice and reinforce implicit associations between positive traits [e.g., "sweet," "attractive," pictures of smiling actors; unconditioned stimuli (US)] and self-referential stimuli [e.g., "I," participant avatars; conditioned stimuli (CS)]. Side tasks such as a "lexical decision" task (indicating whether each target was a real word or a random string of letters) and a fast mouse tracking task (clicking the location of a stimulus as quickly as possible) were used to enhance task engagement and to facilitate semantic and visual processing of the stimuli. Similar forms of "evaluative conditioning" have been found to alter certain measures of implicit self-esteem in healthy participants [Martijn MV, Roefs A, Huijding J, Jansen A: Increasing body satisfaction of body concerned women through evaluative conditioning using social stimuli. Health Psychol.2010;29(5):514-20;Dijksterhuis A:I like myself but I don't know why:enhancing implicit self-esteem by subliminal evaluative conditioning.J Pers Soc Psychol.2004;86(2):345-55;Baccus JR,Baldwin MW,Packer DJ:Increasing implicit self-esteem through classical conditioning.Psychol Sci.2004;15(7):498-502], emotional response to stress [Dijksterhuis A:I like myself but I don't know why:enhancing implicit self-esteem by subliminal evaluative conditioning.J Pers Soc Psychol.2004;86(2):345-55], and pathological behavior (anxiety avoidance [Clerkin EM,Teachman BA:Training implicit social anxiety associations:an experimental intervention.J Anxiety Disord. 2010; 24(3): 300-8], self-injury [Franklin JC, Fox KR, Franklin CR, Kleiman EM, Ribeiro JD, Jaroszewski AC, Hooley JM, Nock MK: A brief mobile app reduces nonsuicidal and suicidal self-injury: Evidence from three randomized controlled trials. J Consult Clin Psychol. 2016; 84(6): 544-57]). The simulated NT includes exactly the same computer task, but uses a neutral rather than positive US and a non-self-related CS (words related to "others", photos of gender-matched strangers), which is designed to eliminate the possibility of unintentional self-referential or negative iatrogenic learning, while providing a credible "brain training" paradigm that controls all nonspecific factors and facilitates patient blinding. .
[0122] Statistical analysis. Intention-to-treat linear mixed-effects regression models were applied, with continuous MADRS score as outcome; day after infusion as random, continuous within-subject effect; and treatment assignment as fixed between-subject effect. Separate models were designed to test two discrete hypothesized linear patterns based on: (1) the infusion phase of the intervention (ketamine vs. saline), using only pre-infusion and 24-hour assessments (collected before the start of active / sham NT); and (2) the NT phase of the intervention (three groups: saline + NT vs. ketamine + sham NT vs. ketamine + NT), using assessment points from 24 hours to day 30. During the infusion phase, a rapid reduction in symptoms was hypothesized in the ketamine group (relative to saline).During the NT phase, we hypothesized that symptoms would increase linearly from 24 h to day 30 in the ketamine + mock NT group (relative to the group * time interaction for saline + NT), consistent with previous published work [Xu Y, Hackett M, Carter G, Loo C, Galvez V, Glozier N, Glue P, Lapidus K, McGirr A, Somogyi AA, Mitchell PB, Rodgers A: Effects of low-dose and very low-dose dose ketamine among patients with major depression: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2015; Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB, Treatments APACoRTFoNBa: Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. Am J Psychiatry. 2015; 172(10): 950-66; Caddy C, Amit BH, McCloud TL, Rendell JM, Furukawa TA, McShane R, Hawton K, Cipriani A: Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev. 2015; Sep23(9): CD011612], the improvement provided by a single infusion of ketamine was consistent over a 1-2 week period; whereas a stable (main) effect was observed from 24 hours to day 30 in the ketamine + active NT group (vs. saline + NT). The NT stage model used the saline + NT group as the reference group for hypothesis testing and included the pre-infusion MADRS score as a covariate. All models included random intercepts and slopes for participants to model patient-level trajectories over time and automatically handled missing data (5.1% of all expected observations). For ease of interpretation, continuous variables were standardized and dichotomous variables were coded as .5 and -.5. Standardized coefficients (β*) and odds ratios (OR) with 95% profile likelihood confidence intervals are reported.Analyses were performed using R version 3.6.
[0123] For descriptive and clinical characterization purposes only, a dichotomous outcome was defined at each post-infusion assessment point for responders (≥50% reduction from pre-infusion MADRS baseline) and remitters (MADRS≤9 [Hawley CJ, Gale TM, Sivakumaran T, Hertfordshire Neuroscience Research g: Defining remission by cut off score on the MADRS: selecting the optimal value. J Affect Disord. 2002; 72(2): 177-84]).
[0124] Sensitivity analyses (see Examples 6-8) explored the robustness of the study findings when including the following pre-selected covariates: sex, age, treatment resistance (moderate vs. severe), and use of concomitant psychotropic medications (dichotomized into yes / no).
[0125] Example 4
[0126] result
[0127] Depression severity—infusion phase. Consistent with previous work, ketamine rapidly reduced MADRS total depression scores 24 hours after infusion (group × time interaction: standardized β = -1.30, 95% CI: -1.89, -0.70; t = -4.29, df = 150, p < .0001; Fig. 9 This moderate to large linear effect corresponds to a 52% response rate and a 28% remission rate among ketamine-treated participants and a 25% response rate and a 4% remission rate among saline-treated participants [number needed to treat (NNT) for response = 3.7; NNT for remission = 4.2].
[0128] Depression severity—NT phase (ASAT phase). In the intention-to-treat linear mixed model, depression scores remained consistently lower in the ketamine+ASAT group relative to the saline+ASAT group over the 30-day acute phase (β=-0.61, 95% CI=-0.95, -0.28; t=-3.62, df=148, p=0.0004; Fig. 9 ), with no corresponding group × time interaction (β = 0.009, 95% CI = -0.004, 0.021; t = 1.39, df = 568, p = 0.164; Fig. 9), indicating durability of effect within the 30-day window. In contrast, depression scores in the ketamine+sham group followed an increasing linear trajectory from 24 hours to 30 days as the post-ketamine effect gradually diminished, with depression score levels approaching those of the saline+ASAT group (group by time interaction relative to saline+ASAT: β=0.015, 95% CI=0.003, 0.03; t=2.35, df=568, p=0.019). The above intention-to-treat statistical test for the linear trajectory over the entire 30-day period was used for statistical hypothesis testing, while pairwise post hoc comparisons conducted at day 30 were used to generate point estimates of effect sizes to further describe the clinical impact at this specific time point. These point estimates of effect sizes suggest that ketamine + ASAT had a small favorable effect relative to both saline + ASAT (β = -0.38, 95% CI = -0.78, 0.027) and ketamine + mock (β = -0.31, 95% CI = -0.75, 0.13).
[0129] All of the above findings were robustly supported in sensitivity analyses controlling for covariates (see Examples 6-8).
[0130] Adequacy of blinding. As shown in Table S1 ( Fig.10 ), patients and raters were effectively not blinded to infusion condition (ketamine vs. saline). While 35% of saline-treated patients incorrectly guessed that they had received ketamine, 99% of ketamine-treated patients (all but one) correctly guessed that they had received ketamine. In both groups (ketamine- and saline-treated participants), clinician ratings of allocation were significantly correlated with symptom reduction (percent change from baseline MADRS) at the time point when blinding was assessed (30 days postinfusion; r ≥ .46, p ≤ .001). In contrast, patient ratings of allocation were significantly correlated with symptom reduction in the saline group (r = .49; p = .001) but not in the ketamine group (r = .01; p = .95). These patterns suggest that, although clinicians' correct guesses about allocation may be more consistently influenced by the degree of clinical improvement, other infusion-day experiences that patients personally learned about (e.g., dissociative side effects) likely also contributed to their correct guesses (regardless of the degree of clinical improvement).
[0131] In contrast, blinding of both patients and assessors to the NT condition was adequate. Patients' mean responses to both conditions (Active = 54%; Sham = 49%; t 143 =1.28; p = .20) reflected the middle of the 0-100% response selection scale of “I don’t know,” as did the clinician responses (active = 55%; simulated = 53%; t 147=0.60; p = .55).
[0132] Example 5
[0133] discuss
[0134] In this study, cognitive training—a low-cost, fully automated, noninvasive, brief (≤20 min / session, delivered over 8 sessions), computer-based intervention—successfully prolonged the rapid antidepressant effects of a single ketamine infusion for at least 30 days. As in previous work, intravenous ketamine demonstrated rapid antidepressant effects in patients with treatment-resistant depression. Ketamine infusions also appeared to successfully open a clinical window of opportunity relative to saline infusions, facilitating the effective uptake of new positive self-representations to protect against depressive relapse in the subsequent month ( Fig. 9 ). In contrast, the same NT protocol, when given without prior treatment with ketamine, did not demonstrate clear beneficial effects on depressive symptoms beyond and above the nonspecific effects of saline infusion and the overall clinical study context (e.g., repeated depression assessments). The second comparison group, ketamine followed by sham NT, followed the expected trajectory of a single ketamine infusion as a stand-alone treatment, with a rapid decline followed by a gradual relapse of symptoms over the following weeks. This is the first study to test ketamine in combination with a behavioral intervention and to include a no-ketamine and no-behavioral control. Similarly, clinical trials pairing various putative "psychoplasticity promoters" or other brain-based targeted approaches (e.g., neuromodulation) with behavioral treatments have almost universally ignored one or the other of these two key comparators [Wilkinson ST, Holtzheimer PE, Gao S, Kirwin DS, Price RB: Leveraging Neuroplasticity to Enhance Adaptive Learning: The Potential for Synergistic Somatic-Behavioral Treatment Combinations to Improve Clinical Outcomes in Depression. 2019; 85(6): 454-65]. The treatment protocol design described herein provides critical new evidence for the putative synergy between ketamine's acute effects of enhancing neuroplasticity and the induction of protective learning delivered via behavioral treatment.
[0135] Although the present disclosure contemplates a range of traditional and non-traditional behavioral treatments that may work in synergy with rapid drug action, this study specifically focuses on the NT approach for both practical and scientific reasons. In practice, NT interventions are mechanistic and portable, and are designed to be highly effective, making them well suited to the brevity of ketamine's window of opportunity (i.e., approximately 1 week). In contrast, a full course of traditional or computer-based cognitive behavioral therapy (CBT) typically requires 12 to 16 1-hour sessions delivered once a week, and meta-analysis suggests that computer-based CBT is most effective when supported only by therapist guidance [Andersson G, Cuijpers P: Internet-based and other computerized psychological treatments for adult depression: a meta-analysis. Cogn Behav Ther. 2009; 38(4): 196-205]. From a scientific perspective, a solid evidence base suggests that implicit and explicit forms of cognition are distinct entities, and that implicit cognition (e.g., implicit self-concept) may be more robust predictors of future behavior than explicit thought content [Greenwald AG, Poehlman TA, Uhlmann EL, Banaji MR: Understanding and using the Implicit Association Test: III. Meta-analysis of predictive validity. J Pers Soc Psychol. 2009; 97(1): 17-41]. NT is designed to efficiently and directly target implicit cognition, resulting in an innovative approach with the potential to efficiently and profoundly shape future behavior and experience. In addition, by targeting a single and well-defined implicit cognitive mechanism, NT can limit the influence of heterogeneous and nonspecific factors that may have an impact in many traditional behavioral interventions and because learning from these factors occurs within a brief window may be more difficult to predict and constrain (e.g., positive vs. negative therapy session experiences).
[0136] NT that specifically targets implicit self-representations was chosen based on previous work suggesting that the best synergistic effects might be achieved when targeting this specific form of information processing after first initiating brain plasticity with ketamine. Two previous studies found evidence for rapid plasticity of implicit self-representations after ketamine [Price RB, Iosifescu DV, Murrough JW, Chang LC, Al Jurdi RK, Iqbal SZ, Soleimani L, Charney DS, Foulkes AL, Mathew SJ: Effects of ketamine on explicit and implicit suicidal cognition: arandomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014; 31(4):335-43; Price RB, Nock MK, Charney DS, Mathew SJ: Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009; 66(5):522-6], suggesting that ketamine creates the necessary plasticity of information processing in this area. Similarly, previous neuroimaging work has demonstrated changes in activity and connectivity in prefrontal and striatal networks following ketamine (e.g., increased caudate nucleus activation and increased striatum-mPFC connectivity during face processing [Murrough JW, Collins KA, Fields J, DeWilde KE, Phillips ML, Mathew SJ, Wong E, Tang CY, Charney DS, Iosifescu DV: Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder. Transl Psychiatry. 2015;5:e509]).Since the striatum and mPFC play extensive roles in appetitive conditioning in humans and rodents [Martin-Soelch C, Linthicum J, Ernst M: Appetitive conditioning: neural bases and implications for psychopathology. Neurosci Biobehav Rev. 2007; 31(3): 426-40], these findings are also potentially consistent with a synergistic match between the neural effects of ketamine and appetitive conditioning paradigms, such as the one used in the present study. Overall, evaluative conditioning techniques have a large and solid literature in healthy controls [Hofmann W, DeHouwer J, Perugini M, Baeyens F, Crombez G: Evaluative conditioning in humans: a meta-analysis. Psychol Bull. 2010; 136(3): 390-421] and in clinical samples, strong and replicable acute clinical effects have previously been shown in a home (smartphone) delivery modality [Franklin JC, Fox KR, Franklin CR, Kleiman EM, Ribeiro JD, Jaroszewski AC, Hooley JM, Nock MK: A brief mobile app reduces nonsuicidal and suicidal self-injury: Evidence from three randomized controlled trials. J Consult Clin Psychol. 2016; 84(6): 544-57]. The ability to achieve and sustain results through portable and highly disseminable technology is a key criterion for overcoming intractable barriers to health care access, particularly for underserved communities [Atdjian S, Vega WA: Disparities in mental health treatment in USracial and ethnic minority groups: implications for psychiatrists. Psychiatr Serv. 2005; 56(12): 1600-2]. Finally, the role of the "depressive self-schema" in creating susceptibility to negative emotions is one of the oldest and best documented cognitive mechanisms mediating depression. 53 , suggesting that this mechanistic target has strong clinical relevance.
[0137] Conclusions. The global burden of depression is extremely high and is expected to continue to increase in the context of the current major pandemic. Novel treatments, especially those that can provide effective relief, are urgently needed. The treatment protocol described here helps advance an integrative plasticity-based model of depression, revealing a novel synergistic treatment approach that can rapidly bring relief and effectively prolong that relief through a safe, low-cost, and portable technology. Along with fully automated NT, ketamine itself also has characteristics that make it more accessible than many alternative approaches, including a favorable safety profile of a single infusion, current FDA approval and widespread international medical use as a general anesthetic, and a high “name recognition” among patients and clinicians.
[0138] Example 6
[0139] Neurocognitive training technical details
[0140] All neurocognitive training (active or simulation) sessions were delivered in a private office on a laptop computer running E-Prime 2 software (Psychology Software Tools; Pittsburgh PA) and Windows operating system. Positive and neutral word lists and photos were selected from stimulus sets previously validated in previous studies.
[0141] Each NT session consisted of three consecutive blocks: (1) a subthreshold lexical evaluative conditioning block; (2) a suprathreshold lexical evaluative conditioning block; and (3) a picture evaluative conditioning block.
[0142] In the subliminal lexical evaluative conditioning block, 60 trials were presented consecutively in random order. Each trial consisted of a fixation string ('XXXX'; 500 ms) in the center of the screen, followed by a single-letter probe (active NT: 'I', implicitly 'self'; simulated NT: 'A') for 17 ms; followed by a positive word (active NT) or a neutral word (simulated NT) for 17 ms; followed by a final probe string consisting of random letters, presented until a response was made. The participant's task was to press a key to indicate whether the final random letter string began with a vowel (left key; 50% of trials) or a consonant (right key; 50% of trials).
[0143] In the suprathreshold lexical evaluative conditioning block, 60 trials were presented consecutively in random order. Each trial consisted of fixation on a word string ('XXXX'; 500 ms), followed by presentation of a single-letter probe (active NT: 'X' or 'I'; simulated NT: 'X' or 'A') for 500 ms; followed by either a real word or a random letter string, presented until a response was made. In the active NT group, the letter 'X' always preceded the random letter string, while the letter 'I' (implied to mean 'self') always preceded the positive words. In the simulated NT group, the letter 'X' always preceded the random letter string, while the letter 'I' always preceded the negative words. The participant's task was to press a key to indicate whether the final letter string was a word (left key; 50% of trials) or a nonword (right key; 50% of trials).
[0144] In the picture evaluation conditioning block, 480 trials were presented consecutively in random order (with a self-administered break in between). Each trial consisted of a screen divided into 4 quadrants and a single picture probe that was presented until the participant clicked the mouse in the correct quadrant; after the mouse click, the first picture was immediately replaced by a second picture in the same position, which was presented for 400 ms. The trial is shown in Figure 3 In the active NT condition, the first (probe) picture in 33% of the trials consisted of one of three digital photos of the participant taken at the screening visit, and the participant was taught to use a neutral facial expression. The headshot photos were taken at a standardized distance, occupying the entire vertical frame, and taken at three standardized angles (front, 45° left, and 45° right). Whenever the first picture was a photo of the participant himself, the second replacement photo condition consisted of a happy facial expression randomly selected from the happy expressions of seven male actors and seven female actors in the standardized NimStim image set [Tottenham N, Tanaka JW, Leon AC, McCarry T, Nurse M, Hare TA, Marcus DJ, Westerlund A, Casey BJ, Nelson C: The NimStim set of facial expressions: judgments from untrained research participants. Psychiatry Res 2009; 168 (3): 242-9]. In the remaining 66% of trials in the active NT condition, the first (probe) picture consisted of digital photographs of strangers in the same three orientations, taken from the standardized Karolinska Directed Emotional Faces (KDEF) image set (Lundqvist, D., Flykt, A., & A.; 1998); the second (replacement) picture consisted of a second neutral facial expression (33% of the trials) or an angry facial expression (33% of the trials), which was randomly selected from the standardized angry and neutral expressions of seven male and seven female actors in the standardized NimStim image set. In the simulated NT condition, the first (probe) picture was a standardized Karolinska Directed Emotional Faces (KDEF) image set (Lundqvist, D., Flykt, A., & A.; 1998). The second replacement photo consisted of a second neutral facial expression (66% of the trials) or an angry facial expression (33% of the trials), which was randomly selected from the standardized angry and neutral expressions of seven male and seven female actors in the standardized NimStim image set.
[0145] Example 7
[0146] Measurement of covariates
[0147] At the screening assessment, participants completed a universal self-report demographic form and medical history form and provided a complete list of their current medications (including dose and indication). This information was used to quantify the following indicators used as covariates in sensitivity analyses: age, biological sex assigned at birth (as listed on their birth certificate), and concurrent use of any concomitant psychotropic medications. Patients were asked about the date of their last psychotropic medication adjustment to ensure that >4 weeks had passed from the last adjustment to the screening assessment (which was equivalent to a stable dose of approximately 6 weeks before the infusion date) and were asked to maintain stable doses of medications and other psychiatric therapies (e.g., psychotherapy) until the infusion day and then throughout the 30-day post-infusion acute phase of the study. The severity of past resistance to FDA-approved antidepressant treatment, assessed by a clinical interviewer using the ATRQ and dichotomized as moderate (<3 failed trials in the current episode) or severe (≥3 failed trials in the current episode), was used for stratified randomization (in addition to sex assigned at birth) and as an additional covariate in sensitivity analyses.
[0148] Example 8
[0149] Adequacy of blinding
[0150] At the final (+30 days) visit, both patients and clinical raters assessed the adequacy of blinding to infusion and NT assignment using a 0-100 sliding scale (0 = definitely placebo / sham; 50 = I don't know; 100 = definitely ketamine / active). Fig.10As shown in Table S1, patients and raters were effectively blinded to infusion condition (ketamine vs. saline). Although 35% of saline-treated patients incorrectly guessed that they had received ketamine, 99% of ketamine-treated patients (all but one) correctly guessed that they had received ketamine. In both groups (ketamine- and saline-treated participants), clinician ratings of allocation were significantly correlated with symptom reduction (percent change from baseline MADRS) at the time point of assessment blinding (30 days postinfusion; r ≥ .46, p ≤ .001). In contrast, patient ratings of allocation were significantly correlated with symptom reduction in the saline group (r = .49; p = .001) but not in the ketamine group (r = .01; p = .95). These patterns suggest that, although clinicians' correct guesses about allocation may be more consistently influenced by the degree of clinical improvement, other infusion-day experiences that patients personally learned about (e.g., dissociative side effects) likely also contributed to their correct guesses (regardless of the degree of clinical improvement).
[0151] In contrast, blinding of both patients and assessors to the NT condition was adequate ( Fig.10 , Table S1). The mean patient response to both conditions (active = 54%; mock = 49%; t 143 =1.28; p = .20) reflected the middle of the 0-100% response selection scale of “I don’t know,” as did the clinician responses (active = 55%; simulated = 53%; t 147 =0.60; p = .55).
[0152] Although few previous ketamine studies have reported explicit measures of successful blinding, the issue of inadequate blinding has been viewed as a challenge in conducting randomized controlled trials of ketamine, given its unique acute effects on cognition, even when a psychoactive comparator (e.g., midazolam) is used [Wilkinson ST, Farmer C, Ballard ED, Mathew SJ, Grunebaum MF, Murrough JW, Sos P, Wang G, Gueorguieva R, Zarate CA, Jr.: Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology 2019;44(7):1233-8; Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CM, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney J, DS, Mathew SJ: Antidepressant efficacy of ketamine in treatment-resistant major depression: A Two-site randomized controlled trial. Am J Psychiatry 2013; 170(10): 1134-42]. An inert placebo was chosen here because a large amount of previous work has demonstrated that ketamine has a definite clinical efficacy in the treatment of depression compared with inert placebo conditions and psychoactive placebo conditions [[Wilkinson ST, Farmer C, Ballard ED, Mathew SJ, Grunebaum MF, Murrough JW, Sos P, Wang G, Gueorguieva R, Zarate CA, Jr.: Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant.Neuropsychopharmacology 2019;44(7):1233-8; Xu Y, Hackett M, Carter G, Loo C, Galvez V, Glozier N, Glue P, Lapidus K, McGirr A, Somogyi AA, Mitchell PB, Rodgers A: Effects of low-dose and very low-dose dose ketamine among patients with major depression: a systematic reviewand meta-analysis.Int JNeuropsychopharmacol 2015; Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB, Treatments APACoRTFoNBa: Ketamineand Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms inDepression.Am JPsychiatry 2015;172(10):950-66; Caddy C,Amit BH, McCloud TL, Rendell JM, Furukawa TA, McShane R, Hawton K, Cipriani A: Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev 2015; Sep 23(9): CD011612], and the present design facilitated a clear comparison of the potential synergistic effects between ketamine and NT without introducing the potential confounding or confounding (either positive or negative) neurocognitive effects of a second psychoactive substance. Indeed, a significant response to saline was observed in our sample (25% responders at 24 hours; reductions from baseline were maintained throughout the 30-day assessment period—. Fig. 9), which provides some reassurance that the saline group successfully controlled for many nonspecific factors (including but not limited to expectation effects) that can affect the outcomes of depression treatment trials [Dunlop BW, Thase ME, Wun CC, Fayyad R, Guico-Pabia CJ, Musgnung J, Ninan PT: A meta-analysis of factors impacting detection of antidepressantefficacy in clinical trials: the importance of academic sites. Neuropsychopharmacology 2012; 37(13):2830-6].
[0153] Example 9
[0154] Described below is an analysis of self-report data collected during a one-year naturalistic follow-up to explore the full extent of the persistence of the automated neurocognitive training protocol described in the Examples herein.
[0155] 154 adult patients with treatment-resistant depression who were in stable psychiatric care were randomly assigned to one of three treatment conditions [Price RB, Spotts C, Panny B, Griffo A, Degutis M, Cruz N, et al.: A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial. Am J Psychiatry. 2022: appiajp20220216]: a single ketamine infusion (0.5 mg / kg) followed by 4 days (30-40 minutes per day) of ASAT, a digital therapy designed to exploit a hypothesized post-ketamine plasticity "window" to target self-related implicit thought patterns; ketamine followed by simulated ASAT (the same computer exercises lacking the therapeutic and self-related content); or saline infusion followed by active ASAT. Throughout the 1-year naturalistic follow-up period, patients completed the Quick Inventory of Depressive Symptomatology (QIDS-SR [Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al.: The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C) and Self-Report (QIDS-SR): A Psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003; 54: 573-83]), which was designated as the primary outcome during the follow-up phase. Surveys were conducted at the following time points relative to the infusion date: +30, +60, +90, +120, +150, +180, and +360 days.
[0156] Time point and group (with saline plus ASAT as the reference group) were included as categorical factors in an intention-to-treat stratified linear model (which automatically imputed missing values) to predict QIDS-SR total score, while covariates included baseline QIDS-SR score before infusion.
[0157] A significant time point*group interaction was observed in the full model (standardized F(12,718)=3.15; p=0.0002). To dissect this interaction, given the lack of a priori knowledge about the potential durability of this first-of-its-kind intervention, visual inspection of symptom trajectories was used to identify data-driven turning points where visible error bars began to overlap at ≥120 days post-infusion ( Fig.13 ).
[0158] exist Fig.13 In the figure, blue lines represent ketamine + active automated self-association training (ASAT), n = 53; orange lines represent ketamine + mock ASAT, n = 50; red lines represent saline + active ASAT, n = 51. Line graphs represent mean values, and error bars represent standard errors of the mean within each time point and treatment group. Gray dashed boxes indicate the "late" period during which no significant pairwise group differences were observed between any two groups at any time point. Pre-infusion baseline and 1 day post-infusion (immediately after ketamine or saline, before the start of active / mock ASAT) are plotted here for comprehensive visualization, but follow-up statistical analysis was focused on the period starting at 30 days after infusion (as described in the text). *Indicates the time point at which the ketamine + active ASAT group had a significant decrease relative to the saline + active ASAT group according to an unpaired t-test.
[0159] To minimize multiple comparisons, pairwise planned contrasts were then used to explore group means within the “early” (≤90 days) and “late” (≥120 days) time periods of these data drives. Fig.13 As shown, in the "early" time period, there was a significant effect of the ketamine + ASAT group compared with the saline + ASAT group (β [95% CI] = -0.37 [-0.71, -0.04]; SE = 0.168; t (144) = -2.21; p = 0.0287), while there was no corresponding significant effect when ketamine was given without ASAT (ketamine + mock) compared with the saline + ASAT group (β = -0.197 [-0.54, 0.14]; SE = 0.172; t (144) = -1.147; p = 0.253). In contrast, in the "late" time period, there were no longer any significant differences between the groups (ketamine+ASAT vs. saline+ASAT: β=0.179; SE=0.168; t(144)=1.068; p=0.287; ketamine+sham vs. saline+ASAT: β=0.111; SE=0.170; t(144)=0.653; p=0.515).
[0160] This study is the first to show that ketamine's rapid effects can be made more durable with a simple, portable digital technology that would be relatively easy to deliver to patients in a variety of settings. According to new follow-up phase data presented here, a single 40-minute drug administration followed by 4 days (30-40 minutes per day) of digital practice produced a statistically significant effect on depression that persisted for 3 months—even in the presence of natural treatment variation in all groups.
[0161] Although the subject matter has been described in language specific to structural features and / or methodological acts, it should be understood that the subject matter defined in the appended claims is not necessarily limited to the specific features or acts described above. Rather, the specific features and acts described above are disclosed as exemplary forms of implementing the claims.
Claims
1. A method for treating a patient suffering from a mental disorder, comprising: administering to the patient a drug having an antidepressant effect; as well as A neurocognitive training protocol is administered to the patient during a critical time period after administration of the drug, wherein administering the neurocognitive training protocol to the patient comprises delivering a plurality of automated neurocognitive training sessions to the patient using a computing device, wherein during delivery of each of the automated neurocognitive training sessions, a plurality of conditioning sequences are presented to the patient, each respective conditioning sequence comprising a respective non-self-relevant stimulus and a respective self-relevant stimulus.
2. The method according to claim 1, wherein: Delivering a first automated neurocognitive training session and a second automated neurocognitive training session to the patient on a first day, and A third automated neurocognitive training session and a fourth automated neurocognitive training session are delivered to the patient on the second day.
3. The method according to claim 2, wherein: The time period between delivery of the first and second automated neurocognitive training sessions to the patient is about 20 minutes or longer.
4. The method according to claim 2 or 3, wherein: The time period between delivery of the third and fourth automated neurocognitive training sessions to the patient is about 20 minutes or longer.
5. The method according to any one of claims 1 to 4, wherein: Each of the automated neurocognitive training sessions has a duration of between about 15 minutes and about 20 minutes.
6. The method according to claim 1, wherein: The plurality of automated neurocognitive training sessions ranges from about 2 sessions to about 14 sessions.
7. The method according to claim 1, wherein: The plurality of automated neurocognitive training sessions is approximately 8 sessions.
8. The method according to any one of claims 1 to 7, wherein: Each respective conditioning sequence further includes a task that is presented to the patient subsequent to or in conjunction with presentation of a respective non-self-relevant and self-relevant stimulus pair.
9. The method according to any one of claims 1 to 8, wherein: The respective non-self-relevant stimulus and / or the respective self-relevant stimulus used for the respective conditioning sequence is an auditory stimulus.
10. The method according to any one of claims 1 to 8, wherein: The respective non-self-relevant stimulus and / or the respective self-relevant stimulus used for the respective conditioning sequence is a visual stimulus.
11. The method according to any one of claims 1 to 8, wherein: The respective self-relevant stimuli used in the respective conditioning sequences include sounds, images or words that are associated with the patient.
12. The method according to claim 11, wherein: The respective non-self-relevant stimuli used in the respective conditioning sequences include sounds, images, or words associated with positive meanings.
13. The method according to claim 11, wherein: The respective non-self-relevant stimuli used in the respective conditioning sequences include sounds, images, or words associated with life-affirming meanings.
14. The method according to any one of claims 1 to 8, wherein: The respective non-self-related stimuli and the respective self-related stimuli for the respective conditioning sequences are included in an nxm matrix including a plurality of visual stimuli.
15. The method according to claim 14, wherein: Administering the neurocognitive training protocol to the patient further includes receiving from the patient a selection of the respective non-self-relevant stimulus to match the respective self-relevant stimulus for the respective conditioning sequence.
16. The method according to any one of claims 1 to 13, wherein: One or more of the plurality of conditioning sequences comprises subliminal presentation of a non-self-relevant stimulus or a self-relevant stimulus.
17. The method according to any one of claims 1 to 13, wherein: One or more of the plurality of conditioning sequences comprises suprathreshold presentation of a non-self-relevant stimulus or a self-relevant stimulus.
18. The method according to any one of claims 1 to 17, wherein: The computer device includes a processor and a memory operatively connected to the processor, the memory having computer-executable instructions stored thereon.
19. The method according to claim 18, wherein: The memory has computer-executable instructions stored thereon that, when executed by the processor, cause the processor to generate each respective conditional action sequence.
20. The method according to claim 19, wherein: The computer device further comprises a display device operably connected to the processor, and wherein the memory has computer executable instructions stored thereon that, when executed by the processor, cause the processor to: generating graphical data for each respective conditioning sequence; and The graphical data is caused to be displayed on the display device.
21. The method according to any one of claims 1 to 20, wherein: The critical time period is the time period during which the drug acutely proliferates synaptic contacts within the patient's brain.
22. The method according to claim 21, wherein: The critical time period is between about 2 hours to about 14 days after administration of the drug.
23. The method according to claim 21, wherein: The critical time period is between about 1 day to about 5 days after administration of the drug.
24. The method according to any one of claims 1 to 23, wherein: The drug is a fast-acting antidepressant.
25. The method according to claim 24, wherein: The fast-acting antidepressant is ketamine.
26. The method according to any one of claims 1 to 23, wherein: The drug is brexanolone, zuranolone, rapastine, scopolamine, or LSD.
27. The method according to any one of claims 1 to 26, wherein: The mental disorder is depression.
28. The method according to any one of claims 1 to 26, wherein: The mental disorder is suicidal behavior.
29. A computer-implemented method for administering a neurocognitive training protocol to a patient with a psychiatric disorder, said patient having received a medication having an antidepressant effect, and administering said neurocognitive training protocol during a critical time period after administration of said medication to said patient, said computer-implemented method comprising: A plurality of automated neurocognitive training sessions are delivered to the patient, wherein a plurality of conditioning sequences are presented to the patient during delivery of each of the automated neurocognitive training sessions, each respective conditioning sequence comprising a respective non-self-relevant stimulus and a respective self-relevant stimulus.
30. The computer-implemented method of claim 29, wherein: Delivering a first automated neurocognitive training session and a second automated neurocognitive training session to the patient on a first day, and A third automated neurocognitive training session and a fourth automated neurocognitive training session are delivered to the patient on the second day.
31. The computer-implemented method of claim 30, wherein: The time period between delivery of the first and second automated neurocognitive training sessions to the patient is about 20 minutes or longer.
32. A computer-implemented method according to claim 30 or 31, wherein: The time period between delivery of the third and fourth automated neurocognitive training sessions to the patient is about 20 minutes or longer.
33. A computer-implemented method according to any one of claims 29 to 32, wherein: Each of the automated neurocognitive training sessions has a duration of between about 15 minutes and about 20 minutes.
34. The computer-implemented method of claim 29, wherein: The plurality of automated neurocognitive training sessions ranges from about 2 sessions to about 14 sessions.
35. The computer-implemented method of claim 29, wherein: The plurality of automated neurocognitive training sessions is approximately 8 sessions.
36. A computer-implemented method according to any one of claims 29 to 35, wherein: Each respective conditioning sequence further includes a task that is presented to the patient subsequent to or in conjunction with presentation of a respective non-self-relevant and self-relevant stimulus pair.
37. A computer-implemented method according to any one of claims 29 to 36, wherein: The respective non-self-relevant stimulus and / or the respective self-relevant stimulus used for the respective conditioning sequence is an auditory stimulus.
38. A computer-implemented method according to any one of claims 29 to 36, wherein: The respective non-self-relevant stimulus and / or the respective self-relevant stimulus used for the respective conditioning sequence is a visual stimulus.
39. A computer-implemented method according to any one of claims 29 to 36, wherein: The respective self-relevant stimuli used in the respective conditioning sequences include sounds, images or words that are associated with the patient.
40. The computer-implemented method of claim 39, wherein: The respective non-self-relevant stimuli used in the respective conditioning sequences include sounds, images, or words associated with positive meanings.
41. The computer-implemented method of claim 39, wherein: The respective non-self-relevant stimuli used in the respective conditioning sequences include sounds, images, or words associated with life-affirming meanings.
42. A computer-implemented method according to any one of claims 29 to 36, wherein: The respective non-self-related stimuli and the respective self-related stimuli for the respective conditioning sequences are included in an nxm matrix including a plurality of visual stimuli.
43. The computer-implemented method of claim 42, further comprising receiving a selection of the respective non-self-relevant stimulus to be matched with the respective self-relevant stimulus for the respective conditioning sequence.
44. A computer-implemented method according to any one of claims 29 to 43, wherein: One or more of the plurality of conditioning sequences comprises subliminal presentation of a non-self-relevant stimulus or a self-relevant stimulus.
45. A computer-implemented method according to any one of claims 29 to 43, wherein: One or more of the plurality of conditioning sequences comprises suprathreshold presentation of a non-self-relevant stimulus or a self-relevant stimulus.
46. The computer-implemented method of any one of claims 29 to 45, further comprising generating each respective conditioning sequence.
47. The computer-implemented method of claim 46, further comprising: generating graphical data for each respective conditioning sequence; as well as The graphical data is caused to be displayed on a display device.
48. A computer-implemented method according to any one of claims 29 to 47, wherein: The critical time period is the time period during which the drug acutely proliferates synaptic contacts within the patient's brain.
49. The computer-implemented method of claim 48, wherein: The critical time period is between about 2 hours to about 14 days after administration of the drug.
50. The computer-implemented method of claim 48, wherein: The critical time period is between about 1 day to about 5 days after administration of the drug.
51. A system for administering a neurocognitive training protocol to a patient suffering from a psychiatric disorder, said patient having received a medication having an antidepressant effect, and administering said neurocognitive training protocol during a critical time period after administration of said medication to said patient, said system comprising: a processor and a memory operatively connected to the processor, the memory having computer executable instructions stored thereon, the computer executable instructions, when executed by the processor, causing the processor to: delivering a plurality of automated neurocognitive training sessions to the patient, wherein: A plurality of conditioning sequences are presented to the patient during delivery of each of the automated neurocognitive training sessions, each respective conditioning sequence comprising a respective non-self-relevant stimulus and a respective self-relevant stimulus.
52. The system of claim 51, wherein: Delivering a first automated neurocognitive training session and a second automated neurocognitive training session to the patient on a first day, and A third automated neurocognitive training session and a fourth automated neurocognitive training session are delivered to the patient on the second day.
53. The system of claim 52, wherein: The time period between delivery of the first and second automated neurocognitive training sessions to the patient is about 20 minutes or longer.
54. A system according to claim 52 or 53, wherein: The time period between delivery of the third and fourth automated neurocognitive training sessions to the patient is about 20 minutes or longer.
55. A system according to any one of claims 51 to 54, wherein: Each of the automated neurocognitive training sessions has a duration of between about 15 minutes and about 20 minutes.
56. The system of claim 55, wherein: The plurality of automated neurocognitive training sessions ranges from about 2 sessions to about 14 sessions.
57. The system of claim 55, wherein: The plurality of automated neurocognitive training sessions is approximately 8 sessions.
58. A system according to any one of claims 51 to 57, wherein: Each respective conditioning sequence further includes a task that is presented to the patient subsequent to or in conjunction with presentation of a respective non-self-relevant and self-relevant stimulus pair.
59. A system according to any one of claims 51 to 58, wherein: The respective non-self-relevant stimulus and / or the respective self-relevant stimulus used for the respective conditioning sequence is an auditory stimulus.
60. The system of any one of claims 51 to 58, wherein: The respective non-self-relevant stimulus and / or the respective self-relevant stimulus used for the respective conditioning sequence is a visual stimulus.
61. A system according to any one of claims 51 to 58, wherein: The respective self-relevant stimuli used in the respective conditioning sequences include sounds, images or words that are associated with the patient.
62. The system of claim 61, wherein: The respective non-self-relevant stimuli used in the respective conditioning sequences include sounds, images, or words associated with positive meanings.
63. The system of claim 61, wherein: The respective non-self-relevant stimuli used in the respective conditioning sequences include sounds, images, or words associated with life-affirming meanings.
64. A system according to any one of claims 51 to 63, wherein: The respective non-self-related stimuli and the respective self-related stimuli for the respective conditioning sequences are included in an nxm matrix including a plurality of visual stimuli.
65. A system according to any one of claims 51 to 64, wherein: One or more of the plurality of conditioning sequences comprises subliminal presentation of a non-self-relevant stimulus or a self-relevant stimulus.
66. The system according to any one of claims 51 to 65, wherein One or more of the plurality of conditioning sequences comprises suprathreshold presentation of a non-self-relevant stimulus or a self-relevant stimulus.
67. The system of claims 51 to 66, wherein: The memory also has computer-executable instructions stored thereon that, when executed by the processor, cause the processor to generate each respective conditional action sequence.
68. The system of claim 67, wherein: The memory also has computer executable instructions stored thereon that, when executed by the processor, cause the processor to: generating graphical data for each respective conditioning sequence; and The graphical data is caused to be displayed on a display device.
69. A method for treating a patient suffering from a mental disorder, comprising: administering to the patient a drug having an antidepressant effect; as well as administering a neurocognitive training protocol to the patient during a critical time period after administration of the drug, wherein administering the neurocognitive training protocol to the patient comprises delivering a plurality of automated neurocognitive training sessions to the patient using a computing device, wherein each respective automated neurocognitive training session comprises: presenting to the patient, using the computing device, an nxm matrix comprising a plurality of visual stimuli, the plurality of visual stimuli comprising a first matched pair of non-self-correlated and self-correlated visual stimuli; and A selection of a first matching pair of non-self-relevant and self-relevant visual stimuli is received by the patient using the computing device.
70. The method of claim 69, wherein: Each individual automated neurocognitive training session also includes: presenting a second matched pair of non-self-relevant and self-relevant visual stimuli to the patient using the computing device; and A task is presented to the patient using the computing device after or in connection with presentation of a second matched pair of non-self-relevant and self-relevant visual stimuli.
71. The method of claim 70, wherein: Each individual automated neurocognitive training session also includes: presenting self-relevant visual stimuli to the patient using the computing device; presenting a task to the patient using the computing device after or in connection with presentation of the self-related stimulus; and Presenting a positive non-self-relevant visual stimulus using the computing device after the patient successfully completes the task.
72. The method of any one of claims 69 to 71, wherein: Each of the automated neurocognitive training sessions has a duration of between about 15 minutes and about 20 minutes.
73. The method according to any one of claims 69 to 71, wherein: The critical time period is the time period during which the drug acutely proliferates synaptic contacts within the patient's brain.
74. The method of claim 73, wherein: The critical time period is between about 2 hours to about 14 days after administration of the drug.
75. The method of claim 73, wherein: The critical time period is between about 1 day to about 5 days after administration of the drug.
76. A computer-implemented method for administering a neurocognitive training protocol to a patient with a psychiatric disorder, said patient having received a medication having an antidepressant effect, and administering said neurocognitive training protocol during a critical time period after administration of said medication to said patient, said computer-implemented method comprising: presenting to the patient an nxm matrix comprising a plurality of visual stimuli, the plurality of visual stimuli comprising a first matched pair of non-self-related and self-related visual stimuli; as well as A selection of a first matched pair of non-self-relevant and self-relevant visual stimuli by the patient is received.
77. A system for administering a neurocognitive training protocol to a patient suffering from a psychiatric disorder, said patient having received a medication having an antidepressant effect, and administering said neurocognitive training protocol during a critical time period after administration of said medication to said patient, said system comprising: a processor and a memory operatively connected to the processor, the memory having computer executable instructions stored thereon, the computer executable instructions, when executed by the processor, causing the processor to: presenting to the patient an nxm matrix comprising a plurality of visual stimuli comprising a first matched pair of non-self-related and self-related visual stimuli; and A selection of a first matched pair of non-self-relevant and self-relevant visual stimuli by the patient is received.
78. A method for treating a patient suffering from a mental disorder, comprising: administering to the patient a drug having an antidepressant effect; as well as A neurocognitive training protocol is administered to the patient during a critical time period after administration of the drug, wherein administering the neurocognitive training protocol to the patient comprises delivering a plurality of automated neurocognitive training sessions to the patient using a computing device, wherein a plurality of conditioning sequences are presented to the patient during delivery of each of the automated neurocognitive training sessions.
79. A method for conditioning a therapeutic association in a patient, comprising: administering a neuroplasticity enhancing therapy to said patient; as well as A neurocognitive training protocol is administered to the patient during a critical time period after administration of the neuroplasticity enhancing therapy, wherein administering the neurocognitive training protocol to the patient comprises delivering to the patient, using a computing device, one or more conditioning sequences configured for conditioning a therapeutic association.
80. The method of claim 79, wherein: The neuroplasticity enhancing treatment is a drug or a neuromodulatory intervention.
